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Foreword  
 
In November 2018, the heads of the UN system came together through the Chief Executives 
Board to forge a common position on the question of global drug policy to advance security, 
development and human rights. This action was in response to the growing need to provide 
multidimensional support to Member States on drug related matters.  
  
Our efforts are rooted in a shared understanding: by integrating analysis and assistance we can 
address prevention and treatment, promote alternative development and access to essential 
medicines, and enhance justice and law enforcement responses that stop organized crime and 
protect people.  
 
To help boost coordination across the system and deliver more effective assistance, we 
established a Task Team to produce timely briefs and encourage joint-programming and 
resource mobilization for drug-related programmes. 
 
This first such brief is a collection of successful experiences in law enforcement, prevention, 
health care, human rights and development over the last ten years. It is a tool for sharing best 
practices and promoting evidence-based, rights-based approaches. 
 
I strongly encourage interested parties to support the work of this Task Team. I have no doubt 
that, together, we can reduce supply and demand, protect health and human rights, and 
contribute to sustainable development, as envisaged in the outcome document of the 2016 
United Nations General Assembly Special Session on Drugs. 
 
Let us continue to strengthen our shared commitments and accelerate progress in addressing 
the world drug problem in the comprehensive way that our experience proves yields the most 
effective results. 
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1. Introduction 
 
Drug markets are evolving at unprecedented speed. The range of substances and combinations 
available to users has never been wider, and the amounts produced have never been greater. 
Cultivation and manufacturing of heroin and cocaine have reached record highs, synthetic 
drugs continue to expand, and the market for new psychoactive substances (NPS) remains 
widely diversified with a growing interplay with traditional drug markets. The non-medical use 
of regulated prescription drugs (either diverted from licit channels or illicitly manufactured) is 
becoming a major threat: in addition to the ongoing opioid epidemic in North America, there 
are signs of an opioid epidemic due to the non-medical use of tramadol in North and sub-
Saharan Africa, as well as in the Middle East. Drug-related deaths are on the rise. At the same 
time, access to controlled drugs for medical purposes remains a dramatic problem in most low- 
and middle-income countries.  
Reasons for blooming drug markets are complex and diversified. A combination of poverty, 
limited social and economic opportunities of rural communities, political instability, lack of 
government control, and changed strategies of trafficking organizations has driven the high 
level of illicit crop cultivation. There remain multiple factors at individual, micro and macro 
level that affect the vulnerability to drug use and its path to harmful use. While progress has 
been made by some countries to increase the accessibility to human-rights and evidence-
based policy interventions, challenges remain with insufficient investment and implementation 
of schemes to prevent, treat and reduce the potential harms posed by drug use. In contrast to 
an increasing trend of donors’ commitment for overall international assistance, assistance in 
the sectors of alternative development and “narcotics control” has significantly declined since 
2008. 1  Punitive drug policies continue to be used in some communities, despite being 
ineffective in reducing drug trafficking or in addressing non-medical drug use and supply, and 
continue to undermine the human rights and well-being of persons who use drugs, as well as 
of their families and communities.    
    
The SDG 2030 Agenda is putting the dignity, health and rights of people and planet at the 
centre of sustainable development.  
Drug matters are intertwined with all aspects of sustainable development. All areas of the 
17 Sustainable Development Goals shape the nature and dynamic of the drug problem. At the 
same time, the impact of the drug problem and the response thereto on development can be 
observed at individual, community and national levels. For example, ensuring healthy lives and 
promoting well-being for all (SDG 3) requires effective measures to address the world drug 
problem, while the lucrative drug trade compounds corruption risk and undermines 
responsive, accountable and transparent institutions at all levels (SDG 16). 
 
When well-designed drug policy interventions directly or indirectly result in an improvement 
in the level of development of their target populations, operations designed to improve 
sustainable development can address the vulnerability of people or communities affected by 
the drug problem and can ultimately help address it. However, if not based on human rights 
standards and a solid evidence base, drug policies can have a counterproductive effect on 
                                                      
1 UNODC, World Drug Report 2016 (United Nations publication, Sales No. E.16.XI.7). 
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development. Abusive, repressive and disproportionate drug control policies and laws are 
counterproductive, while also violating human rights, undercutting public health and wasting 
vital public resources. 
 
The outcome document of UNGASS 2016 highlighted the need to strengthen cooperation 
among UN entities in their efforts to address the world drug problem, and the need to promote 
the protection of and respect for human rights by supporting Member States in the 
implementation of the operational recommendations contained in that document. On 
7 November 2018, members of the Chief Executives Board for Coordination (CEB) committed 
to supporting each other’s activities so as to deliver a “truly balanced, comprehensive, 
integrated, evidence-based, human rights-based, development-oriented and sustainable 
support to Member States in implementing joint commitments to address the world drug 
problem, including the operational recommendations contained in the outcome document of 
the 2016 UN General Assembly Special Session on the World Drug Problem”. The CEB also 
established a UN system coordination Task Team composed of all interested UN entities and 
led by UNODC, for the purposes of coordinating data collection to promote scientific, evidence-
based implementation of international commitments. 
 
2. Health, including the availability of and access to controlled 
medicines 
 
2.1 Introduction 
 
Extent of drug use and overall impact on health 
 
Global extent of drug use in numbers  
People aged 15–64 years who used drugs at 
least once in the previous year (2016) 
275 million 5.6 per cent 
Cannabis 192 million 3.9 per cent 
Opioids 
Opiates 
34.3 million 
19.4 million 
0.70 per cent 
0.40 per cent 
Cocaine 18.2 million 0.37 per cent 
Amphetamines and prescription 
stimulants 
34.2 million 0.70 per cent 
Ecstasy 20.6 million 0.42 per cent 
People aged 15–16 years old who used 
cannabis at least once during the previous 
year (2016) 
13.8 million 5.6 per cent 
People aged 15–64 years who suffer from 
drug use disorders (2016) 
30.5 million 0.62 per cent 
People who injected drugs – PWID – (2016) 10.6 million 0.22 per cent 
Percentage of people who inject drugs and 
their sexual partners among newly infected 
people with HIV outside of sub-Saharan 
Africa 
 25 per cent 
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People who injected drugs living with HIV 
(2016) 
1.3 million 11.8 per cent of PWID 
People who injected drugs living with  
hepatitis C (2016) 
5.5 million 51.9 per cent of PWID 
Deaths attributed to the use of drugs (2017) 585,000 72 per cent of deaths 
among males 
“Healthy” life lost (DALYs) 42 million years 70 per cent of years 
of life lost by males 
Source: UNODC, World Drug Report 2018; Institute for Health Metrics and Evaluation, Global Burden of Disease 
Data; UNAIDS, Global AIDS Update 2018 – Miles to Go (Geneva, 2018); UNAIDS estimates. 
 
Drug use is linked to a range of health, social and protective factors. Thanks to the large body 
of scientific literature, there is today a better understanding of what increases an individual’s 
vulnerability to initiating the use of substances and what leads to drug use disorders.2 Lack of 
knowledge about substances and their consequences, genetic predisposition, personality traits 
(e.g. impulsivity, sensation seeking), the presence of mental health conditions and behavioural 
disorders, family neglect and abuse, poor attachment to school and the community, social 
norms and environments conducive to substance use (including the influence of media), and 
growing up in marginalized, stigmatized and deprived communities are among the main 
vulnerability factors. Conversely, psychological and emotional well-being, personal and social 
competence, a strong attachment to caring and effective parents, attachment to schools and 
communities that are well resourced and organized are all protective factors that contribute 
to individuals being less vulnerable to illicit drug use and other risky behaviours.3 
 
Some of the vulnerability and resilience factors differ according to age. Parenting and 
attachment to school are important during infancy, childhood and early adolescence. At older 
ages, schools, workplaces, entertainment venues and the media contribute to making 
individuals more or less vulnerable to drug use and other risky behaviours.4 Marginalized youth 
in poor communities who have little or no family support, as well as limited access to education 
in school, are especially at risk. So are children, individuals and communities torn or displaced 
by war or natural disasters.5 Higher socioeconomic groups have a greater propensity to initiate 
illicit drug use than lower socioeconomic groups, but it is the lower socioeconomic groups that 
pay the higher price as they are more likely to become drug dependent.6 
 
Vulnerability factors are largely out of the control of the individual and are linked to a multitude 
of social, environmental and health conditions, requiring interventions that address not only 
drugs but also other risk factors.7 
 
The extent of illicit drug use has a negative impact in achieving SDG 3 “Ensure healthy lives and 
promote well-being for all at all ages”, not only because of the medical conditions resulting 
                                                      
2 UNODC/WHO, International Standards on Drug Use Prevention, Second updated edition (Vienna, 2018).  
3 Ibid.  
4 Ibid. 
5 Ibid. and UNHCR/WHO, Rapid Assessment of Alcohol and Other Substance Use in Conflict-affected and 
Displaced Populations: A Field Guide.  
6 UNODC, World Drug Report 2016 (United Nations publication, Sales No. E.16.XI.7).  
7 UNODC/WHO, International Standards on Drug Use Prevention, Second updated edition (Vienna, 2018). 
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directly from the psychoactive and physiological effects of drugs, but also because of the risk 
factors associated with certain forms of drugs and modes of administration.    
 
Limited access to services, including health services, and exclusion from relevant host 
population programmes, may exacerbate the harmful consequences of illicit drug use and its 
negative impact on SDG 3,8 while also undermining the human rights obligations to address 
the HIV epidemic within the community of people who use drugs.9 
 
Drug use among women 
 
Men are three times more likely than women to use cannabis, cocaine and amphetamines, 
whereas women are more likely than men to have a non-medical use of prescription opioids 
and tranquillizers. Existing research points to unequal opportunities (also relating to social and 
cultural norms) in access to illicit drug markets as one of the reasons for differences in the 
prevalence of drug use between men and women. In addition, drug use during pregnancy may 
lead to health problems for the pregnant woman and fetus, especially when combined with 
alcohol use, malnutrition and low access to health care. Women who use drugs can face 
substantial barriers to accessing services, including HIV services – facing lack of accessible 
services, stigma and discrimination,10 in breach of their human rights and undermining the 
achievement of SDG 5 “Achieve gender equality and empower all women and girls”.  
 
Service uptake in general and for pregnant women in particular can be improved where there 
is support from family members, social connections within the health-care system and referral 
services from NGOs11 and if health workers provide the advice, support, treatment and care in 
line with the international guidelines developed for this purpose.12 Mothers with a history of 
drug use often fear accessing health and social services due to stigma and discrimination and 
due to legislation that may declare them unfit to parent, while pregnant women may be 
pressured to have abortions or to give up newborn infants.13 There have been reports of 
women who use drugs during pregnancy being arrested, confined and forced to undertake 
medical treatment, sometimes without evidence that they have drug dependency or that the 
health of the fetus is at risk, in clear violation of their rights to freedom from forced treatment, 
arbitrary detention and to fair trial.14 Avoiding stigma and discrimination against women in 
health care settings and elsewhere increases their accessibility to services. As WHO has noted, 
                                                      
8 UNHCR/WHO, Rapid Assessment of Alcohol and Other Substance Use in Conflict-affected and Displaced 
Populations: A Field Guide. 
9 A/65/255. 
10 UNODC, World Drug Report 2018 (United Nations publication, Sales No. E.18.XI.9). 
11 UNAIDS, The Gap Report (Geneva, 2014). 
12 WHO, Guidelines for the identification and management of substance use and substance use disorders in 
pregnancy (Geneva, 2014). 
13 UNAIDS, Do no harm – health, human rights and people who use drugs (Geneva, 2016). 
14 Report of the Special Rapporteur on the right of everyone to the enjoyment of the highest attainable standard 
of physical and mental health, 3 August 2011, A/66/254, paras. 38, 39; Report of the Working Group on 
Arbitrary Detention on its visit to the United States of America, 17 July 2017, A/HRC/36/37/Add.2, paras. 72–74; 
Report of the Working Group on Arbitrary Detention on its visit to the United States of America, 17 July 2017, 
A/HRC/36/37/Add.2, para. 73. 
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“It is important that all women from key populations have the same support and access to 
services related to conception and pregnancy care, as women from other groups.”15  
 
Access to controlled drugs for medical purposes, particularly for the treatment of pain 
 
The medical use of narcotic drugs continues to be indispensable for the relief of pain and 
suffering and ensuring their availability for such purposes is essential. Making internationally 
controlled drugs available for medical and scientific purposes is at the heart of the international 
drug control conventions since the Single Convention on Narcotic Drugs of 1961. The United 
Nations human rights mechanisms also recognized that ensuring access to essential drugs is 
an essential element of the right to health.16 This principle has continued to be emphasized as 
the cornerstone of international drug policy in CND resolutions and in the outcome document 
of the 2016 UN General Assembly Special Session on the World Drug Problem. Achieving a 
balance between ensuring the availability of narcotic drugs and psychotropic substances under 
international control for medical and scientific purposes and preventing their diversion and 
abuse is at the core of the international drug control system. Both sides of this balance – 
ensuring availability and preventing diversion and abuse – are concerned with the protection 
and promotion of health and public safety and directly relate to the achievement of SDG 3, 
including Target 3.b “Support the research and development of vaccines and medicines … 
provide access to affordable essential medicines …”. 
 
Despite international attention, it is clear that there is a large burden of untreated pain around 
the world with 80 per cent of the world’s population still without access to controlled 
medicines. 17 ,  18  There is a significant divide: approximately 90 per cent of the morphine 
worldwide is consumed by only 17 per cent of the global population living primarily in a few 
Western countries.19, 20 Barriers to accessibility of controlled drugs for medical use include the 
limited capacity of health care professionals due to lack of university curricula on the use of 
pain medications that are evidence-based, and national policies that may not meet the 
regulatory requirements across the full spectrum of the supply chain for controlled essential 
medicines. 
 
The right to health  
 
The dignity of human beings, and their right to health, is the cornerstone of effective 
international drug policy. Health is a fundamental human right indispensable for the exercise 
of other human rights. The enjoyment of the right to health includes, inter alia, access to health 
facilities, goods and services that are scientifically and medically appropriate and of good 
                                                      
15 WHO, Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. 
16 A/HRC/30/65, para. 33, A/65/255, paras. 40–47, 76. 
17 UNODC, Ensuring availability of controlled medications for the relief of pain and preventing diversion and 
abuse: Striking the right balance to achieve the optimal public health outcome, Discussion paper based on a 
scientific workshop held in Vienna on 18–19 January 2011. 
18 UNODC, Technical guidance: Increasing access and availability of controlled medicines, Advanced draft (March 
2018). 
19 INCB, Special Reports, beginning in 2010. 
20 INCB, Special Report: Availability of Internationally Controlled Drugs: Ensuring Adequate Access for Medical 
and Scientific Purposes (2015). 
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quality, and the “right to be free from interference, such as the right to be free from torture, 
non-consensual medical treatment and experimentation”.21  
 
The enjoyment of the highest attainable standard of health applies to every human being 
without distinction of race, religion, political belief, economic or social condition.22 The right to 
health for all people means that everyone should have access to the health services they need, 
when and where they need them, without suffering financial hardship.23, 24 Yet only one in six 
persons with drug use disorders benefits from drug treatment services.25 
 
Incorporating public health, the reduction of harm from drug use – referred by some 
practitioners as harm reduction – and gender-sensitive approaches into national drug 
strategies, while ensuring the availability of treatment services that are evidence-based and 
respectful of the rights of persons who use drugs, their families and communities, in 
accordance with international human rights obligations.26 Under the right to health and the 
right to life, individuals, including children, have a right to services to reduce the harm of non-
medical use of drugs that are accessible, available, acceptable and of good quality.27, 28 
 
Stigma and discrimination in health care settings can have a significant effect on accessing 
services, including HIV testing and treatment. Studies among people who inject drugs found 
that respondents were almost seven times as likely to avoid HIV testing if they had been 
previously refused treatment or services by health care workers.29 Negative attitudes of health 
care workers towards people with drug use disorders can negatively affect key populations 
(KPs).30 Of the 117 countries reporting to UNAIDS in 2017, only 18 reported that they had anti-
discrimination laws or provisions that apply to people who use drugs (either through health 
status or disability).31 
 
                                                      
21 CESCR, General comment No. 14 (2000), E/C.12/2000/4, para. 12 (d). 
22 UNGA, International Covenant on Economic, Social and Cultural Rights, article 2.2., in conjunction with 16 
December 1966, United Nations, Treaty Series, vol. 993, p. 3. 
23 Preamble to the Constitution of the WHO. Available at https://www.who.int/governance/eb/who 
_constitution_en.pdf. 
24 UN General Assembly, International Covenant on Economic, Social and Cultural Rights, article 2.2., in 
conjunction with 16 December 1966, United Nations, Treaty Series, vol. 993, p. 3. 
25 UNODC, World Drug Report 2018 (United Nations publication, Sales No. E.18.XI.9). 
26 See E/C.12/CAN/CO/6, E/C.12/ESP/CO/5, E/C.12/PHL/CO/5-6, E/C.12/GRC/CO/2, E/C.12/MKD/CO/2-4 and 
E/C.12/SWE/CO/6. 
27 See e.g. CESCR, Concluding Observations on the combined fifth and sixth periodic reports of the Philippines, 
E/C.12/PHL/CO/5-6 (2016), para. 54; CESCR, Concluding Observations on the combined second to fourth 
periodic reports of the former Yugoslav Republic of Macedonia, E/C.12/MKD/CO/2-4 (2016), para. 52; Report of 
the Special Rapporteur on the right of everyone to the enjoyment of the highest attainable standard of physical 
and mental health, Anand Grover (2010), A/65/255, para. 55. 
28 CRC, General comment No. 21 on children in street situations (2017), CR/GC/21 (2017), para .53; CRC, 
General comment No. 15 on the right of the child to the highest attainable standard of health (2013), 
CRC/C/GC/ 15, para 66. 
29 Ti L, Hayashi K, Kaplan K, Suwannanwong P, Wood E, Montaner J et al., “HIV test avoidance among people 
who inject drugs in Thailand”, AIDS and Behavior, vol. 17, No. 7 (2013), pp. 2474–2478. 
30 Thailand, Ministry of Public Health, International Health Policy Program, Measuring HIV-related Stigma and 
Discrimination in Health Care Settings in Thailand: Report of a pilot: Developing Tools and Methods to Measure 
HIV-related Stigma and Discrimination in Health Care Settings in Thailand (2014). 
31 See http://www.aidsinfoonline.org/ncpi/libraries/aspx/Home.aspx. 
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The criminalization of drug use for other purposes than medical and scientific ones can have a 
negative effect on the enjoyment of the right to health. It can increase stigma and 
discrimination and thus deter affected persons from seeking treatment and rehabilitation 
services, thereby rendering them more vulnerable to violence and abuse from both private 
and state agencies.  
 
Stigma created or reinforced through punitive enforcement or treatment regimes may also 
increase health risks. Policing practices ranging from surveillance to use of excessive force have 
been noted to target vulnerable and marginalized populations, which may increase the risks of 
physical and mental health issues for people who use drugs. It can lead to higher rates of risky 
injection practices and can increase risks of overdose due to lack of access to clean syringes or 
safe injecting rooms, the need to inject quickly and in unsafe places, and being driven from 
areas where services to minimize the harm of drug use are provided, all of which can increase 
exposure to HIV and other blood borne infections.32 
 
2.2 Prevention of illicit drug use and drug use disorders and promoting healthier 
populations at different levels and sectors 
 
Substance use most commonly begins in adolescence, with alcohol, tobacco and cannabis 
being the substances most commonly used by children and young people. Early onset of 
frequent substance use is associated with the increased risk of developing dependence or 
harmful use later in life, as well as being linked with physical and mental health problems, 
although there is no clear causal relationship. Effective prevention starts early and is based on 
the best available scientific evidence. Many sectors have a role to play, primarily the health 
sector, but the education sector can also play a key role in protecting children and young 
people from substance use, 33  and at the same time can promote an environment where 
seeking treatment for problematic drug use is not stigmatized.  
 
SDG Target 3.5 “Strengthen the prevention and treatment of substance abuse, including 
narcotic drug abuse and harmful use of alcohol” defines the importance of providing 
prevention and treatment services in the context of sustainable development. The second 
updated edition of the UNODC and WHO International Standards on Drug Use Prevention34 
summarizes the currently available scientific evidence on interventions and policies that have 
been found to be effective in preventing drug use, as well as other related risky behaviours.  
 
Effective interventions and policies have been identified across many settings (family, school, 
community, workplace, health sector, etc.) and levels of risk (universal, selective and 
indicated). 35  In infancy and early childhood, effective actions are: prenatal and infancy 
visitation, interventions targeting pregnant women, and early childhood education. For middle 
childhood (approximately 5 to 10 years of age), effective strategies include: parenting skills 
programmes (effective also in early adolescence), personal and social skills education, 
classroom environment improvement programmes, policies to retain children in school, as well 
                                                      
32 A/65/255 paragraph 24. 
33 UNESCO/UNODC/WHO, Education sector responses to the use of alcohol, tobacco and drugs (Paris, 2017). 
34 See https://www.unodc.org/unodc/en/prevention/prevention-standards.html. 
35 Ibid. 
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as addressing mental health disorders (relevant also in adolescence). In early adolescence, 
additional effective strategies include: prevention education based on social competence and 
influence, school policies on substance use, school-wide programmes to enhance school 
attachment, addressing individual psychological vulnerabilities, and mentoring. In later 
adolescence and adulthood, additional effective strategies include: brief intervention, tobacco 
and alcohol policies, as well as multi-component programmes in the workplace, in the 
community and in entertainment venues. Media campaigns can also play an important 
supportive role 36 without stigmatizing people who use drugs. 
 
There is limited research on the different factors that may influence a different efficiency of 
prevention programmes for males and females. The little available evidence points to some 
different etiological factors for women and girls.37  
 
Commercial determinants of health in the case of legally produced and distributed substances 
such as dependence-producing prescription drugs can also influence the scope and nature of 
drug use. The rapidly growing cannabis industry has become a new part of the private 
commercial sector in some countries that can promote cannabis products and choices that 
could be detrimental to health. These conditions are additional elements that can make 
prevention activities and policies more or less effective.    
 
Health professionals are in a unique position to identify psychoactive substance use among 
their clients and intervene at an early stage before substance use disorders and serious related 
problems develop. There is substantial accumulated evidence of the effectiveness of screening 
and brief interventions for hazardous and harmful alcohol use in primary health care settings.38 
Research findings suggest that screening followed by brief interventions can also be effective 
when targeting drugs other than alcohol psychoactive substances. The WHO ASSIST package 
helps health professionals to intervene at early stages of substance use to prevent 
development of substance use disorders.39 
 
 2.3. Treatment of drug use disorders, rehabilitation, recovery and social reintegration 
 
Drug use dependence is a complex, multifactorial health disorder characterized by a chronic 
and relapsing nature that requires a multidisciplinary and comprehensive response, including 
diversified pharmacological and psychosocial interventions.40, 41 
 
The main treatment recommended by WHO for opioid use disorders is opioid substitution 
therapy (OST) with long acting opioids (methadone and buprenorphine, both of which are on 
the WHO List of Essential Medicines).42 OST (also called opioid agonist maintenance 
                                                      
36 Ibid.  
37 UNODC, Guidelines on drug prevention and treatment for girls and women (Vienna, 2016).  
38 Kaner EFS et al. (2018). 
39 WHO, mhGAP Intervention Guide for mental, neurological and substance use disorders in non-specialized 
health settings, Version 2.0 (2016).  
40 UNODC, World Drug Report 2015 (United Nations publication, Sales No. E.15.XI.6). 
41 UNODC, Outcome document of the 2016 United Nations General Assembly Special Session on the World Drug 
Problem: Our joint commitment to effectively addressing and countering the world drug problem (2016). 
42 WHO, Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence (2009). 
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treatment), combined with psychosocial assistance, has been found to be the most 
effective.43 Another option is detoxification followed by relapse-prevention treatment using 
opioid antagonist (naltrexone).44  
 
Psychosocial interventions are the treatment options available for drugs other than opioid.45 
There is no medication proven effective for managing and treating stimulant use disorders.46 
 
With regard to psychosocial interventions, the evidence from clinical trials supports the 
effectiveness of cognitive behavioural therapy (CBT), motivational interviewing (MI), 
community reinforcement approach (CRA), motivational enhancement therapy (MET), family 
therapy (FT), contingency management (CM) and 12-step group facilitation.47 
  
Health care systems oftentimes struggle to appropriately respond to behavioural and medical 
problems caused by different types of drugs. For example, in parts of the world where opioids 
were seldom used, health systems do not have the capacity to deliver medically assisted 
treatment, such as opioid agonist maintenance therapy. Similarly, where the treatment system 
has mainly focused on opioid use disorders, the system is challenged to respond to an increase 
in psychostimulants use disorders for which evidence-based psychosocial treatment is the 
main effective intervention in the absence of evidence-based pharmacological treatment. 
 
As mentioned above, criminalization of drug use and law enforcement practices can act as a 
barrier to accessing treatment, as can concerns of confidentiality, particularly where drug 
registers are utilized. Stigma and discrimination by health care professionals similarly can limit 
willingness to engage in drug dependence treatment.48  
 
Opioid overdose is manageable with naloxone, an opioid antagonist that rapidly reverses the 
effects of opioids. Naloxone can be injected intramuscularly, subcutaneously, intravenously or 
administered intranasally. According to WHO guidelines, community distribution of naloxone 
will reduce overdose deaths.49 Management of opioid overdose with naloxone is expected to 
reduce opioid overdoses that result in death. An overall prevention strategy would also include 
access to effective treatment of opioid use disorders.50 
 
Heroin-assisted treatment refers to the prescription of synthetic, injectable or smokable heroin 
to a minority of people with opioid dependence who do not respond to treatment with one of 
the established medications used in long-acting agonist maintenance therapy, such as 
                                                      
43 Ibid. 
44 Ibid. 
45 UNODC/WHO, Principles of Drug Dependence Treatment (2008); UNODC/WHO, International Standards for 
the Treatment of Drug Use Disorders: Draft for Field Testing (2016).  
46 Ibid. 
47 mhGAP Evidence Resource Centre on drug use disorders; UNODC/WHO, Principles of Drug Dependence 
Treatment (2008); UNODC/WHO, International Standards for the Treatment of Drug Use Disorders: Draft for 
Field Testing (2016). 
48 Report of the Special Rapporteur on the right of everyone to the enjoyment of the highest attainable standard 
of physical and mental health, Anand Grover (2010), A/65/255, paras. 30–39. 
49 WHO 2014. 
50 UNODC/WHO, Opioid Overdose: Preventing and Reducing Opioid Overdose Mortality (2013); WHO, 
Community management of opioid overdose (2014). 
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methadone or buprenorphine. For this small group of patients, heroin-assisted treatment has 
been found effective in improving their social and health situation. It has also been shown to 
be cost-effective, as it reduces costs of arrests, trials, incarceration and health interventions. 
In this approach, patients are provided with a form of pharmaceutical-grade heroin (injection) 
solution.  
 
The public health system is best placed to take the lead in the provision of effective treatment 
services for people affected by drug use disorders, often in close coordination with social care 
services and other community services. 51  The public health approach to drug treatment 
involves the least invasive intervention possible with the highest level of effectiveness and the 
lowest cost possible.52 
 
The right to health includes “the right to be free from … non-consensual medical treatment 
and experimentation.” 53  WHO and UNODC have stated, “The same standards of ethical 
treatment should apply to the treatment of drug dependence as other health care conditions. 
These include the right to autonomy, and self-determination on the part of the patient, and 
the obligation for beneficence and non-maleficence [do good/do no harm] on behalf of 
treating staff.”54 Neither detention nor forced labour is based on evidence of effectiveness and 
they have no therapeutic value as treatment for drug use disorders.55 People who use or are 
dependent on drugs do not automatically lack the capacity to consent to treatment. Therefore, 
treatment should not be forced or against the will and autonomy of the patient and the 
consent of the patient should be obtained before any treatment intervention. In 2012, 12 UN 
entities raised concerns about drug detention centres and rehabilitation centres as places that 
raise human rights issues and threaten the health of detainees and called for their immediate 
closure, for an end to financial and technical support for such centres and for investigations to 
address abuses.56 Incarceration and confinement in compulsory drug treatment centres often 
worsens the lives of drug users and drug dependent individuals, particularly the youngest and 
most vulnerable.57 According to the Special Rapporteurs, compulsory drug treatment centres 
also breach the rights to freedom from arbitrary detention and can amount to torture and 
inhuman and degrading treatment or punishment.58  
                                                      
51 UNODC/WHO, Principles of Drug Dependence Treatment (2008); UNODC/WHO, International Standards for 
the Treatment of Drug Use Disorders: Draft for Field Testing (2016). 
52 Ibid. 
53 CESCR, General comment No. 14 on the right to the highest attainable standard of health, E/C.12/2000/4, 
adopted 11 August 2000, para. 34; see also CESCR, General comment No. 14 on the right to the highest 
attainable standard of health, E/C.12/2000/4, adopted 11 August 2000, para. 34; Report of the Special 
Rapporteur on the right of everyone to the enjoyment of the highest attainable standard of physical and mental 
health (2010), A/64/272; Report of the Special Rapporteur on the rights of persons with disabilities (2018), 
A/73/161, paras. 9, 14–15; see also UNODC/WHO, Principles of Drug Dependence Treatment (2008) p. 9.  
54 UNODC/WHO, Principles of Drug Dependence Treatment (2008).  
55 Ibid.  
56 ILO/OHCHR/UNDP/UNESCO/UNFPA/UNHCR/UNICEF/UNODC/UN Women/WFP/WHO/UNAIDS, Joint 
Statement: Compulsory drug detention and rehabilitation centres. Available at http://www.unodc.org/ 
documents/southeastasiaandpacific//2012/03/drug-detention-centre/JC2310_Joint_Statement6March12FINAL 
_En.pdf. 
57 Jurgens and Betteridge (2005). 
58 Report of the Special Rapporteur on torture and other cruel, inhuman or degrading treatment or punishment, 
Manfred Nowak (2013), A/HRC/22/53, paras. 42, 87(a); Report of the Special Rapporteur on the right of 
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Drug use or drug dependence alone is not sufficient grounds for detention.59 Where drug 
dependence is considered a disability, the Convention on the Rights of Persons with Disabilities 
provides further protection, stating clearly that “the existence of a disability shall in no case 
justify a deprivation of liberty.”60 Compulsory detention, even if it has a basis in law, may also 
constitute arbitrary detention where it is random, capricious or disproportionate – that is, not 
reasonable or necessary in the circumstances of a given case.61 Compulsory treatment for 
people dependent on drugs can only be legally justified in clearly defined exceptional 
circumstances in conformity with international human rights law that guarantees such 
provisions are not subject to abuse. 62  The treatment must be scientifically and medically 
appropriate and of good quality63 and intended to return a person to a state of autonomy over 
their treatment decisions. It must be short term and specifically time bound.64  
 
On several occasions, UN human rights bodies have expressed concerns about reports of poor 
conditions in drug rehabilitation centres and ill-treatment inflicted upon persons admitted to 
them.65 
 
A number of social and structural barriers continue to hinder the access of women to 
treatment for drug use: globally, only one of five drug users in treatment is a woman even 
though one of three drug users is a woman.66 As with men, effective treatment for women 
balances individual needs with their drug use disorder and the cultural, structural, ethnic and 
                                                      
everyone to the enjoyment of the highest attainable standard of physical and mental health, Anand Grover 
(2010), A/65/255, paras. 30–39. 
59 OHCHR, Report of the Working Group on Arbitrary Detention (2015), A/HRC/30/36, para. 60: “Drug 
consumption or dependence is not sufficient justification for detention. Involuntary confinement of those who 
use or are suspected of using drugs should be avoided.”; Report of the Special Rapporteur on torture and other 
cruel, inhuman or degrading treatment or punishment, Juan Mendéz (2013), A/HRC/22/53, paras. 40–42; see 
also Report of the Working Group on Arbitrary Detention (2003), E/CN.4/2004/3, paras. 74, 87; Human Rights 
Committee, General comment No. 35: Article 9 (Liberty and security of person) (2014), CCPR/C/GC/35, para. 15; 
European Court of Human Rights, Witold Litwa v. Poland, Application No. 26629/95, 4 April 2000, paras. 77–80. 
60 CRPD, art 14(1)(b). 
61 Human Rights Committee, General comment No. 35: Article 9 (Liberty and security of person), CCPR/C/GC/35, 
para. 12: “An arrest or detention may be authorized by domestic law and nonetheless be arbitrary. The notion 
of ‘arbitrariness’ is not to be equated with ‘against the law’ but must be interpreted more broadly to include 
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reasonable and necessary in all the circumstances. Aside from judicially imposed sentences for a fixed period of 
time, the decision to keep a person in any form of detention is arbitrary if it is not subject to periodic re-
evaluation of the justification for continuing the detention.”  
62 ILO/OHCHR/UNDP/UNESCO/UNFPA/UNHCR/UNICEF/UNODC/UN Women/WFP/WHO/UNAIDS, Joint 
Statement: Compulsory drug detention and rehabilitation centres.  
63 In accordance with the right to health, see General comment No. 14 on the right to health, para. 12(d). 
64 Human Rights Committee, General comment No. 35: Article 9 (Liberty and security of person), CCPR/C/GC/35, 
para 12: “Aside from judicially imposed sentences for a fixed period of time, the decision to keep a person in any 
form of detention is arbitrary if it is not subject to periodic re-evaluation of the justification for continuing the 
detention.”  
65 See e.g. CAT/C/GTM/CO/5-6; CAT/C/TKM/CO/2; CRC/C/PAK/CO/5; CCPR/C/KHM/CO/2; CRC/C/KHM/CO/2; UN 
Working Group on Arbitrary Detention Report, A7HRC730-36 (2015), p. 17. 
66 UNODC, World Drug Report 2015 (United Nations publication, Sales No. E.15.XI.6). 
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religious factors that may limit their access to evidence-based drug treatment.67 While data 
are limited, there is some evidence that other sub-population groups such as displaced persons 
or refugees are disadvantaged in accessing drug treatment.68  
 
Lesbian, gay, bisexual, transgender and intersex persons who use drugs are disproportionately 
impacted by drug policies in many countries and experience a range of harms flowing from 
drug use and drug-induced mental trauma. Lesbian, gay, bisexual, transgender and intersex 
persons who use drugs may not seek support or treatment from health-care providers because 
of previous or anticipated experiences of discrimination.69 
 
2.4 Minimizing the adverse health consequences of drug use: prevention, treatment 
and care of HIV, viral hepatitis, other blood-borne infections and tuberculosis 
 
In some countries where transmission of HIV and viral hepatitis is concentrated in people who 
inject drugs, the coverage of evidence-based services remains low or non-existent. WHO has 
defined a package of evidence-based prevention, diagnosis and treatment services for HIV and 
hepatitis that include needle and syringe programmes, opioid substitution therapy and 
community distribution of naloxone, as well as testing and treatment of HIV, viral hepatitis B 
and C and TB.  
 
The current low coverage of this package is insufficient to effectively prevent transmission and 
ultimately achieve SDG 3.3 “By 2030, end the epidemics of AIDS, tuberculosis, malaria and 
neglected tropical diseases and combat hepatitis, water-borne diseases and other 
communicable diseases”. Globally, needle and syringe programmes distributed just 33 needles 
and syringes per person who injects drugs per year (instead of recommended 200 for HIV and 
300 for reaching the WHO HCV elimination targets), and only 16 per cent of people who inject 
drugs had access to opioid substitution therapy (instead of the recommended 40 per cent). 
Overall, it is estimated that less than 1 per cent of people who inject drugs live in countries 
where the coverage of these key interventions is sufficient.70 People who inject drugs are at 23 
times greater risk of HIV infection than people who do not inject drugs,71 and incidence is not 
declining. More than 80 per cent of people who inject drugs are either living with, or have 
previously had, a hepatitis C infection.72   
 
The comprehensive package to effectively prevent HIV includes the nine interventions 
described by WHO, UNODC and UNAIDS. The three organizations recommend the provision of 
a comprehensive set of evidence-based services to people who inject drugs. The effectiveness 
                                                      
67 UNODC, Guidelines on drug prevention and treatment for girls and women (Vienna, 2016); WHO, Guidelines 
for identification and management of substance use and substance use disorders in pregnancy (2014). 
68 UNHCR/WHO, Rapid Assessment of Alcohol and Other Substance Use in Conflict-affected and Displaced 
Populations: A Field Guide.  
69 A/HRC/39/39, para. 75. 
70 Sarah Larney and others, “Global, regional, and country-level coverage of interventions to prevent and 
manage HIV and hepatitis C among people who inject drugs: A systematic review”, The Lancet Global Health, 
vol. 5, No. 12, pp. e1208–e1220. 
71 UNAIDS Fact Sheet – World AIDS Day 2018. Available at: www.unaids.org/sites/default/files/media_asset/ 
UNAIDS_FactSheet_en.pdf. 
72 WHO, Global Hepatitis Report 2017 (Geneva, 2017).  
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of a core package of nine services was confirmed in 2009 by the three organizations. In 2014, 
WHO updated the package to include opioid overdose management with naloxone for people 
who inject drugs and pre-exposure prophylaxis as prevention intervention, alongside 
interventions to minimize the adverse health consequences of drug use.73 In addition to the 
health interventions, WHO positioned addressing structural barriers with enabling 
interventions as part of a public health response to HIV for key populations including people 
who inject drugs. Enabling interventions includes reviewing laws and legislation that 
criminalize behaviours such as drug use and possession for personal use, reducing stigma and 
discrimination, including in the health sector, and addressing violence, as well as supporting 
the empowerment of people who use drugs. Their implementation requires a scale-up through 
multiple service delivery models, including outreach, low-threshold drop-in centres and peer 
education. These programmes effectively reduce the sharing of injecting equipment, improve 
quality of life, decrease mortality, reduce crime and public disorder, improve social functioning 
and provide a bridge to drug dependence treatment. 
 
The greatest benefit from HIV and hepatitis C prevention is reported when needle and syringe 
programmes are offered in combination with opioid substitution therapy and their coverage is 
high,74, 75, 76 meaning more than 300 needles or syringes per person who injects drugs per year, 
and more than 40 per cent of people who inject drugs undergoing opioid substitution 
therapy.77 
 
There is strong evidence that high coverage of needle-syringe programmes and opioid 
substitution therapy services — closely linked to condom programming, testing and treatment 
of HIV and viral hepatitis — can have a major public health impact in places with substantial 
populations of people who inject drugs. 78  Opioid substitution therapy has been found to 
                                                      
73 WHO/UNODC/UNAIDS, Technical guide for countries to set targets for universal access to HIV prevention, 
treatment and care for injecting drug users, (Geneva, 2012); WHO, Consolidated guidelines on HIV prevention, 
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77 WHO/UNODC/UNAIDS, Technical guide for countries to set targets for universal access to HIV prevention, 
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review”, AIDS and Behavior, vol. 17, No. 9 (2013), pp. 2878–2892. 
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Health, vol. 14 (2014), p. 853. 
 Jones L, Pickering L, Sumnall H, McVeigh J, Bellis A, “A review of the effectiveness and cost-effectiveness of 
needle and syringe programs for injecting drug users”, Centre for Public Health, Liverpool John Moores 
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improve access and adherence to antiretroviral therapy, reduce instances of overdose and 
associated mortality, and lessen criminal activity.79 Opioid-substitution therapy (OST), needle-
syringe programmes (NSP) and antiretroviral therapy (ART) together have established 
effectiveness in reducing drug dependency, reducing sharing of injecting equipment, 
improving quality of life and averting HIV infections.80 
 
The burden of disease of viral hepatitis attributable to injecting drug use is even higher than 
HIV. Of the 71 million people with chronic HCV, 8 per cent is among people who inject drugs. 
However, 23 per cent of new HCV infections and 33 per cent of HCV related mortality are 
attributable to injecting drug use. The WHO recommendations and elimination targets put a 
strong focus on providing these services as well as prioritizing PWID to test and treat for HCV. 
HCV is curable and countries that have implemented targeted programmes are likely to reach 
the elimination targets.81 
 
The concern of HIV transmission is not only with people who inject drugs such as opioids. There 
is evidence that among people who inject stimulants (cocaine and amphetamines) and among 
men who have sex with men, those who use methamphetamine or amphetamine are more 
likely to engage in higher-risk sexual behaviours and be HIV-positive than those who use other 
drugs.82 A systematic review found that the risk of acquiring HIV was 3.6 times greater among 
people who used cocaine by injection than among those who used cocaine by other means, 
and 3.0 times higher among people who used amphetamine-type stimulants by injection than 
among those who used amphetamine-type stimulants by other means. Most evidence points 
towards a positive association between stimulant use, higher-risk sexual and injecting 
behaviours and HIV infections.83, 84 
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Women who inject drugs are often more vulnerable to HIV than their male counterparts. A 
review of studies in countries with a high prevalence of HIV among people who inject drugs 
(greater than 20 per cent) found a higher overall prevalence of HIV among women who inject 
drugs compared with men who inject drugs.85 Unsafe injecting practices may be more common 
among women because of the lack of services tailored to their needs. 
In many countries, punitive drug policies do not recognize the unique vulnerability of persons 
with psychosocial disabilities who use drugs. Such policies affect them negatively by not 
providing appropriate drug dependence treatment and services to prevent the adverse health 
consequences of drug use.86 
 
2.5 Drug use, dependence, injecting, prevention and treatment in prison settings 
 
Drug use in prison settings: the numbers   
Global prison population (2017) 
90 per cent male 
1 per cent children 
10.7 million 142 people per 
100,000 population 
Prisoners have used a controlled substance 
at some point while incarcerated 
 33 per cent of 
prisoners 
Prisoners who have reported current  
(past month) drug use 
 16 per cent of 
prisoners 
Lifetime prevalence of injection drug use 
within prison 
  
Asia-Pacific  20.2 per cent 
Eastern Europe and Central Asia  17.3 per cent  
Latin America and the Caribbean  11.3 per cent 
Western and Central Europe and 
North America 
 9.3 per cent 
Middle East and North Africa  7.3 per cent 
Other African regions  less than 1 per cent  
People held in prisons who are living  
with HIV  
 3.8 per cent 
People held in prisons who are living  
with hepatitis C  
 15.1 per cent  
People held in prisons who have active 
tuberculosis 
 2.8 per cent  
Source: United Nations Survey on Crime Trends and Operations of Criminal Justice Systems (various years); Note 
by the Secretariat: World crime trends and emerging issues and responses in the field of crime prevention and 
criminal justice, E/CN.15/2014/5; UNODC, World Drug Report 2017; Babak Moazen and others, “Prevalence of 
drug injection, sexual activity, tattooing, and piercing among prison inmates”, Epidemiologic Reviews, vol. 40, 
No. 1, (2018), pp. 58–69; Kate Dolan and others, “Global burden of HIV, viral hepatitis, and tuberculosis in 
prisoners and detainees”, The Lancet, vol. 388, No. 10049 (2016), pp. 1089–1102. 
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Drug-related data on prison populations are limited due to the lack of systematic monitoring 
in many countries. Based on global reviews of available national and subnational studies, it is 
clear that, in many countries and regions, prison settings are likely to be a place with high drug 
use and high-risk injecting practices. But despite this high risk, in some countries, health care 
services provided in prisons are not equivalent to those available in the community. This 
undermines the overarching principle of the implementation of the SDG of not leaving anyone 
behind.  
 
A global systematic review of the literature and national surveys of 189 countries indicated 
that 11 countries provided prison-based NSP. Data also indicated that prison-based OST 
operated in 56 countries. The study indicated HIV testing and treatment were provided in 79 
and 88 countries, respectively.87 
 
People deprived of their liberty (whether in criminal or administrative detention) have a right 
to access health care services, including drug dependence treatment, and services to reduce 
the harm of drug use equivalent to those outside prison. According to the Special Rapporteur 
on torture and other cruel, inhuman or degrading treatment or punishment, for example, the 
denial of methadone treatment in custodial settings has been considered to be a violation of 
the right to be free from torture and ill-treatment in certain circumstances.88 
 
The period shortly after release from prison is associated with a substantially increased risk of 
drug-related death (primarily fatal overdose). Drug-related mortality rate after release from 
prison has been found to be 50–100 times higher than the mortality rate of the general 
population.89, 90  
 
Women in prison often come from socially marginalized groups and compared with women in 
the wider community, they are more likely to have engaged in sex work and/or illicit drug use 
and be living with HIV owing to the combined risks of unsafe injecting practices and 
unprotected sex.91, 92  
 
The nine interventions described in the WHO, UNODC, UNAIDS Technical guide for countries 
to set targets for universal access to HIV prevention, treatment and care for injecting drug users 
93 are appropriate for implementation in prisons and other closed settings. UNODC, ILO, UNDP, 
WHO and UNAIDS94 have defined a specific comprehensive package of interventions for HIV 
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92 Steffanie Strathdee and others, “Substance use and HIV among female sex workers and female prisoners: Risk 
environments and implications for prevention, treatment, and policies”, Journal of Acquired Immune Deficiency 
Syndrome, vol. 69, supplement 2, pp. S110–S117. 
93 See http://www.unodc.org/documents/hiv-aids/publications/People_who_use_drugs/Target_setting 
_guide2012_eng.pdf. 
94 See http://www.unodc.org/documents/hiv-aids/HIV_comprehensive_package_prison_2013_eBook.pdf. 
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prevention, treatment and care in prisons and other closed settings. This package of 15 
interventions includes all the nine interventions targeting PWID as well as additional 
interventions to address broader HIV risk, including interventions for the prevention of 
mother-to-child transmission of HIV; measures to combat sexual violence; post-exposure 
prophylaxis; precautions to prevent transmission through medical and dental services; 
measures to make tattooing, piercing and other forms of skin penetration safer; and 
interventions for staff.95 
 
In general, exposure to the prison environment facilitates affiliation with older criminals and 
criminal gangs and organizations. It also increases stigma and helps to form a criminal identity. 
It often increases social exclusion, worsens health conditions and reduces social skills. 
Alternatives to incarceration within the community (outpatient or residential therapeutic 
setting), such as psychosocially supported pharmacological treatment for opiate dependence, 
can be more effective than imprisonment in reducing reoffending.96 
 
Cost-effectiveness of prevention and treatment and return on investment  
 
Investing in prevention and control of drug use and drug use disorders produce significant 
returns: saved lives, prevented disabilities, healthier populations, improved workforce 
participation and productivity, and reduced criminal justice costs. Every single US$ invested in 
effective treatment of substance use disorders can return to societies between $4 and $12.97 
It has been estimated that expenditure on drug treatment produces savings not only for the 
health system but also for the criminal justice system. 
 
Services aimed at reducing the harm caused by non-medical drug use are also cost effective. 
For example, each dollar spent in a needle-syringe programme can return up to $5.50 in 
averted health-care costs. By comparison, incarceration appears expensive and ineffective.  
 
The unit costs of interventions which minimize the adverse health consequences of drug use 
are relatively low, but can vary by provider type, delivery model and region. Generally, NSP are 
least expensive, while the costs of ART are expected to decline by 2020. OST is a structural 
intervention with other societal benefits: when such benefits are included, the attributable 
cost for HIV budgets and cost effectiveness ratios are highly favourable. In one particular 
country, the expansion of needle-syringe programmes and methadone maintenance therapy 
has seen the proportion of HIV infections acquired through injecting drug use plummet from 
nearly 50 per cent to less than 1 in 10.98 
Although the overall costs of scaling up programmes to minimize the adverse health 
consequences of drug use will be high, it will be a worthwhile action; not only do the societal 
benefits of programmes to minimize the adverse health consequences of drug use exceed their 
treatment costs, but they also have the potential to provide significant returns on investment 
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update (Geneva, 2016). 
96 Chandler et al. (2009). 
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for governments. These interventions can be cost-effective by most thresholds in the short 
term and cost-saving in the long term.99 
 
Stigma and stigmatizing drug policies affect the effectiveness of drug responses 
 
The stigmatizing attitudes towards people who use drugs that may extend to staff in health 
care services can hamper the effectiveness of drug responses, and they are ultimately an 
obstacle in achieving SDG Target 10.2 “By 2030, empower and promote the social, economic 
and political inclusion of all” and SDG Target 10.3 “Ensure equal opportunity and reduce 
inequality of outcome, including by eliminating discriminatory laws, policies and practices and 
promoting appropriate legislation, policies and action in this regard”.   
 
Several studies have identified stigma as a significant barrier to accessing health care and 
treatment services for drug users. Surveys of health professionals have indicated that they may 
hold negative or stereotypical views of people with drug dependence, which are likely to 
compromise the provision of high-quality care, while studies of nurses found that negative and 
punitive attitudes towards people who use drugs can be relatively common. Judgmental, 
unsympathetic or hostile attitudes and views held by health professionals are likely to 
discourage individuals with drug-related problems from accessing health care services. The 
punitive approaches of law enforcement authorities with regard to people who use drugs can 
contribute to their marginalization, particularly when those approaches lead to high levels of 
incarceration.100 
 
Stigma can be reinforced by criminal laws and other structural barriers, which can also fuel 
violence, exploitation and a climate of fear.101 
 
Eleven UN agencies have issued a joint statement on ending discrimination in health care 
settings, calling on all stakeholders to commit to review punitive laws that have been proven 
to have negative health outcomes and that counter established public health evidence, 
including laws that criminalize or otherwise prohibit drug use or possession of drugs for 
personal use.102 
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3. Effective law enforcement and protection of vulnerable 
communities 
3.1 Prevention of drug-related crime 
 
Many of the risk factors associated with crime and violent behaviour are also risk factors of 
drug use, and joint interventions targeting overlapping risk factors can be particularly effective. 
Risk factors of crime include:103individual risk factors (adverse childhood experiences, history 
of violent victimization, mental health disorders, involvement with drugs, alcohol, or tobacco, 
poor behavioural control, being male, youthful); family risk factors (low parental involvement, 
low emotional attachment to parents or caregivers, low parental education and income, 
parental substance abuse or criminality, poor family functioning); community risk factors (low 
social capital in community, low access to medical care, situational factors, diminished 
economic opportunities, high concentrations of poor residents, high level of transiency, high 
level of family disruption, low levels of community participation, socially disorganized 
neighbourhoods, availability of drugs, association with delinquent peers, involvement in gangs, 
social rejection by peers); and societal risk factors (rapid social change, economic inequality, 
poverty, weak economic safety nets, poor rule of law and high corruption, culture of violence, 
gender inequalities, high firearm availability, conflict/post-conflict situation). These risk factors 
show in particular the close interlinkages between sustainable development and drug matters 
as clearly low social development – as related to, for example, SDG 4 (quality education), SDG 
8 (economic growth, full and productive employment and decent work) and SDG 10 
(inequality) – increases the risk of being involved in drug-related crime and drug use.  
 
A large body of literature, although mostly from developed countries, has established a series 
of effective practices to prevent violence and crime (in general, not just drug-related crime),104 
which include: developing safe, stable and nurturing relationships between children and their 
parents and caregivers; 105 developing life skills in children and adolescents; 106  hot spot 
(data/information-driven) policing, problem-oriented policing, and community policing; 107 
community-based responses that improve crime data collection, multisectoral collaboration 
and social cohesion;108  reducing access to firearms and knives (e.g. requiring a license to 
possess a gun and bans on purchases of guns by alcoholics appear to reduce rates of both 
homicide and robbery);109 reducing the availability and harmful use of alcohol;110 promoting 
                                                      
103 WHO, Framework for interpersonal violence prevention (2002); Farrington and Welsh (2007). 
104 See e.g. WHO/UNODC/UNDP, Global Status Report on Violence Reduction (2014), and web portals that 
contain good practices on crime prevention such as https://campbellcollaboration.org/. 
105 See e.g. the UNODC’s Strengthening Families Programme on drug use prevention, which also targets risk 
factors of crime. 
106 See e.g. Elmira Prenatal Home Visitations (US), and the UNODC’s Line Up, Live Up initiative. 
107 See e.g. Silveira, A, Assunção, R, Silva, B and Beato, C, “Impacto do Programa Fica Vivo”, Revista de Saúde 
Pública vol. 44, No. 3 (2010) pp. 496–502. 
108 See e.g. the Cardiff Model on sharing of anonymized data between hospitals and the police, with up to 42 per 
cent reduction in violent injuries; Cure Violence on the use of mediators to de-escalate gang violence and reduce 
homicides; and Communities That Care. 
109 Kleck, Gary & Kovandzic, Tomislav & Bellows, Jon, “Does Gun Control Reduce Violent Crime?”, Criminal 
Justice Review, vol. 41 (2016), pp. 488–513. 
110 WHO/UNODC/UNDP, Global Status Report on Violence Reduction (2014). 
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gender equality to prevent violence against women;111 changing cultural and social norms that 
support violence (through long-term community engagement and IEC, not one-off campaigns); 
victim identification, care and support programmes (to reduce re-victimization); and 
environmental design that reduces the opportunities for crime.112 
 
An aspect related to the prevention of illicit cultivation is linked to inclusive and sustainable 
economic growth, and other income opportunities related to drug production and 
transportation in impacted zones (targets related to SDG 8).  
 
3.2 Response to drug-related crime 
  
Criminal justice response to drug-related crime: global estimates (2017)   
Persons arrested/suspected of drug 
possession  
1.9 million  
Persons arrested/suspected of drug 
trafficking  
1.2 million  
Persons convicted for drug possession for 
personal use  
860,000 44 per cent of those 
arrested for drug 
possession for 
personal use 
Persons convicted for drug trafficking 740,000 60 per cent of those 
arrested for drug 
trafficking 
Number of persons in prison who were 
sentenced for drug possession for personal 
use as the principle offence 
470,000 4 per cent of all 
prison population 
Number of persons in prison who were 
sentenced for drug trafficking as the 
principle offence 
1.7 million 16 per cent of all 
prison population 
Among all persons in prison for any drug-
related offence: 
  
percentage sentenced for drug 
possession for personal use 
 21 per cent of all 
prisoners sentenced 
for drug-related 
offences 
percentage sentenced for drug 
trafficking 
 79 per cent of all 
prisoners sentenced 
for drug-related 
offences 
Source: United Nations Survey of Crime Trends and Operations of Criminal Justice Systems (various years). 
 
                                                      
111 UNODC, Global Study on Homicide Booklet: Gender-related killing of women and girls (2018). 
112 Ha, Taehoon; Oh, Gyeong-Seok and Park, Hyeon-Ho, “Comparative analysis of defensible space in CPTED 
housing and non-CPTED housing”, International Journal of Law, Crime and Justice vol. 43, No. 4, (2015); Bea, 
David C., “Transport engineering and reduction in crime: The Medellín case,” Transportation Research Procedia, 
vol. 18. (2016); Cerda, Magdalena et al., “Reducing violence by transforming neighbourhoods: A natural 
experiment in Medellín, Colombia”, American Journal of Epidemiology, vol. 175, No. 10 (2012). 
25 
 
Data on the number of persons at the various stages of the criminal justice system 
(arrested/suspected, convicted and imprisoned) for drug possession for personal use and drug 
trafficking are available for only a limited number of countries, and show strong regional 
variations.113 
 
The international drug control conventions do not require Parties to criminalize drug use for 
non-medical or non-scientific purposes per se.114 Subject to constitutional principles and basic 
principles of each Party’s legal system, States parties are required to establish as a criminal 
offence the cultivation, possession and purchase for personal consumption of controlled drugs 
for other than medical and scientific purposes. Criminalization of drug use and possession for 
personal use for purposes other than medical and scientific may lead to an increased risk of 
illness among people who use drugs and a negative effect on HIV prevention and treatment. It 
can increase stigma and discrimination, police harassment and arbitrary arrests. Higher rates 
of legal repression have been associated with higher HIV prevalence among people who use 
injecting drugs, without a decrease in prevalence of injecting drug use. This is a likely the result 
of individuals adopting riskier injection practices out of fear of arrest or punishment.115 Of the 
118 countries that report to UNAIDS, national authorities of 10 countries and civil society 
organizations of 16 countries reported that possession of a needle or syringe without a 
prescription can be used as evidence of drug use or cause of arrest.116, 117,  118 
 
The basic principles of the rule of law and access to justice, as also embedded in SDG 16 
“Promote peaceful and inclusive societies for sustainable development, provide access to 
justice for all and build effective, accountable and inclusive institutions at all levels”, require 
the criminal justice response to drug-related crime to be transparent, avoiding arbitrariness 
and consistent with international human rights norms and standards.119 For States to be 
consistent with their human rights obligations, they need to make concerted efforts to 
combat impunity by conducting prompt, independent, impartial and effective investigations 
                                                      
113 United Nations Survey of Crime Trends and Operations of Criminal Justice Systems (various years). 
114 According to the 1988 Convention: “Subject to its constitutional principles and the basic concepts of its legal 
system, each Party shall adopt such measures as may be necessary to establish as a criminal offence under its 
domestic law, when committed intentionally, the possession, purchase or cultivation of narcotic drugs or 
psychotropic substances for personal consumption contrary to the provisions of the 1961 Convention, the 1961 
Convention as amended or the 1971 Convention.” article 3(2). The International Narcotics Control Board has 
explained “the international drug control treaties do grant some latitude with regard to the penalization of 
personal consumption-related offenses. Parties to the 1961 Convention are under an obligation not to permit 
the possession of drugs for personal non-medical consumption. Parties to the 1988 Convention are required to 
establish as criminal offenses activities preparatory to personal consumption, subject to each party’s 
constitutional principles and the basic concepts of its legal system.” 
115 A/65/255, para. 26. 
116 NCPI data. Available at http://www.aidsinfoonline.org/ncpi/libraries/aspx/Home.aspx; Benoit C, McCarthy B, 
Jansson M, “Stigma, sex work, and substance use: a comparative analysis”, Sociology of Health & Illness, vol. 37, 
No. 3 (2015), pp. 437–51.; DeBeck K, Cheng T, Montaner JS, Beyrer C, Elliott R, Sherman S et al., “HIV and the 
criminalization of drug use among people who inject drugs: A systematic review”, The Lancet HIV, vol. 4, (2017), 
pp. e357–e374; see also A/HRC/39/39. 
117 Bourmont M, David S, “Hidden victims of war on drugs”, Phnom Penh Post, 24 February 2017. Available at 
http://www.phnompenhpost.com/national/hidden-victims-wardrugs. 
118 DeBeck K, Cheng T, Montaner JS, Beyrer C, Elliott R, Sherman S et al., “HIV and the criminalization of drug use 
among people who inject drugs: A systematic review”, The Lancet HIV, vol. 4, (2017), pp. e357–e374.  
119 Report of the Secretary-General to the Security Council: The rule of law and transitional justice in conflict and 
post-conflict societies (S/2004/616). 
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into serious human rights violations and bringing alleged perpetrators to justice. At the same 
time, States need to protect the rights of people in criminal proceedings, whether they are 
victims, witnesses, alleged offenders or prisoners. Law enforcement officials also should 
always adhere to the Basic Principles on the Use of Force and Firearms by Law Enforcement 
Officials.120  
 
According to the Human Rights Council’s Working Group on Arbitrary Detention, arbitrary 
detention for drug offences or drug use can occur across criminal and administrative settings, 
particularly when procedural safeguards are absent, causing a disproportionate impact on 
women, children, minority groups and people who use drugs.121 For example, women who 
inject drugs have reported high rates of sexual violence from police and law enforcement 
agencies.122 
 
Structural changes in legislation and law enforcement practices can facilitate the delivery of 
services, including minimizing the adverse consequence of drug use.123 
 
3.3 Countering trafficking in narcotic drugs and psychotropic substances  
 
The achievement of SDG 16, particularly Target 16.4 “By 2030, significantly reduce illicit 
financial and arms flows, strengthen the recovery and return of stolen assets and combat all 
forms of organized crime”, is at the core of the response to countering drug trafficking 
organizations. Vulnerability of one group offers a profit opportunity to another. Organized 
criminal groups have always been resourceful in adapting to change in the markets and in their 
aim to avoid risk of interception. Hierarchical structures have a major weakness: they can be 
easily dismantled when detected by the authorities. As a result, some hierarchical crime groups 
have reshaped their structures in recent decades to become networked organizations. 
Although most identified international organized criminal groups in the European Union 
remain hierarchically organized,124 Europol suggests a trend away from vertical structures 
towards horizontal criminal groups operating along a networked organization model (cellular 
                                                      
120 A/HRC/39/39, paras. 92, 93. 
121 A/HRC/30/36. 
122 Azim T, Bontell I, Strathdee SA, “Women, drugs and HIV”, International Journal of Drug Policy, vol. 26, No. 1 
(2015), pp. s16–s21; Integrated biological and behavioural surveillance reports, 2012–2016; Integrated 
biological and behavioural surveillance reports, 2013–2015; Integrated biological and behavioural surveillance 
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123 Abdul-Quader AS, Feelemyer J, Modi S, Stein ES, Briceno A, Semaan S et al., “Effectiveness of structural-level 
needle/syringe programs to reduce HCV and HIV infection among people who inject drugs: A systematic 
review”, AIDS and Behavior, vol. 17, No. 9 (2013), pp. 2878–2892. 
 Csete J, Kamarulzaman A, Kazatchkine M, Altice F, Balicki M, Cepeda J et al., “Public health and international 
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Commissions, vol. 387, No. 10026 (2016), pp. 1427–1480. 
 Fernandes RM, Cary M, Duarte G, Jesus G, Alarcão J, Torre C et al., “Effectiveness of needle and syringe 
programmes in people who inject drugs: An overview of systematic reviews,” BMC Public Health, vol. 17, No. 
309 (2017). 
WHO/UNODC/UNAIDS, Technical guide for countries to set targets for universal access to HIV prevention, 
treatment and care for injecting drug users, (Geneva, 2009). 
124 Europol, European Union: Serious and Organised Crime Threat Assessment (SOCTA) 2017 (The Hague, 2017). 
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structure and less rigid or permanent hierarchies).125 Loose criminal networks represented 30–
40 per cent of organized criminal groups identified by Europol in 2017.126 
 
Where law enforcement agencies lack resources and are prone to corruption and where justice 
systems are weak and impunity is prevalent, demands on the police to be more effective in 
countering drug trafficking can lead to indiscriminate apprehension of those likely to be 
perceived as criminals. This can also lead law enforcement agents to target the types of crime 
for which suspects are easier to identify, which tend to be minor drug-related offences rather 
than more serious offences such as major drug trafficking and homicide. Zero-tolerance 
policies, if not properly implemented, may run the risk of generating violence by stigmatizing 
and enabling the abuse of power to be directed against people who use drugs or low-level 
players in the drug trafficking chain. This, in turn, can lead to mass imprisonment for low-level 
offences or to forced detention of people who use drugs.127 
 
Strategies that focus on rapidly disrupting drug trafficking organizations and reducing violence 
in the short term can sometimes lead to more violence. By the same token, strategies that 
tackle the root causes of violence in the medium to long term may have a less discernible 
impact on short-term violence reduction. 
 
Research suggests that law enforcement and policing that target the protagonists and 
elements of the drug trafficking chain that generate the highest profits and the most violence 
are more effective in reducing violence than indiscriminate law enforcement by the authorities. 
For example, policing that targets the most violent drug traffickers can reduce violence by 
creating a powerful deterrent to violent behaviour. Targeted law enforcement can also entail 
strategies that do not focus on arresting low-level players in the drug trafficking chain and thus 
tend not to add to mass incarceration problems, which would have little positive (or perhaps 
even a negative) impact on violence.128  
 
The assumption that tougher law enforcement results in higher drug prices and therefore 
lowers the availability of drugs in the market is not supported by the empirical evidence. The 
small number of scientific studies that attempted to make the case have been reviewed over 
the last five years and the findings show that, although prohibition itself raises prices far above 
those likely to pertain in legal markets, there is little evidence that raising the risk of arrest, 
incarceration or seizure at different levels of the distribution system will raise prices at the 
targeted level, let alone retail prices.129 Drug seizures themselves cannot generally be expected 
to disrupt drug markets unless they are extremely large since usually suppliers can easily 
replace the lost drugs at wholesale costs. If the seizure is associated with dismantling an 
organization that had a substantial share of market throughput capacity, then one might 
                                                      
125 Europol, European Union: Serious and Organised Crime Threat Assessment (SOCTA) 2013 (The Hague, 2013). 
126 Europol, European Union: Serious and Organised Crime Threat Assessment (SOCTA) 2017 (The Hague, 2017). 
127 UNODC, World Drug Report 2016 (United Nations publication, Sales No. E.16.XI.7). 
128 Ibid. 
129 Harold A. Pollack and Peter Reuter, “Does tougher enforcement make drugs more expensive?”, Addiction, 
vol. 109, No. 12 (2014), pp. 1959–1966. 
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observe a correlation between seizures and price changes. However, once a market is 
established, there may be little return on an investment in intense law enforcement.130 
 
Data-driven policing, problem-oriented policing and community policing have been found 
more effective approaches to prevent and respond to crime (including drug-related crime).131  
 
In recent years there have been some alarming tendencies towards a deeper militarization of 
the responses by States to counter drug-related crimes. In some instances, this is associated 
with the progressive militarization of civilian police forces. Excessive use of force is more likely 
to occur when military or special security forces are involved in drug operations. Such 
approaches have disproportionately affected vulnerable groups and have repeatedly resulted 
in serious human rights violations.132 
 
3.4 Proportionate and effective policies and responses (including evidence on 
alternatives to incarceration and decriminalization/depenalization of drug use) 
 
The international drug control conventions expressly allow the provision of measures such as 
treatment and education as alternatives to conviction or punishment for personal 
consumption offences and for all other relevant offences in “appropriate cases of a minor 
nature”. Examples of this approach are the diversion of minor cases from the criminal justice 
system through the exercise of police or prosecutorial discretion, and the use of non-custodial 
measures as an alternative to pretrial detention or imprisonment. This is in line with the 
international drug control conventions and with the requirements of an effective and human 
rights-compliant penal policy.133 The excessive use of imprisonment for drug-related offences 
of a minor nature is indeed ineffective in reducing recidivism, as well as having a 
disproportionate effect on the health and well-being of those arrested for minor offences. It 
also overburdens criminal justice systems, preventing them from efficiently coping with more 
serious crime. The provision of evidence-based treatment and care services to drug-using 
offenders, as an alternative to incarceration, has been shown to substantially increase recovery 
and reduce recidivism.134 Even the most costly forms of alternative interventions (such as drug 
courts, though care must be taken to ensure such alternatives do not result in forced treatment) 
are more cost-effective than imprisonment, although those approaches require effective 
coordination between the health and justice systems.135 Overuse of imprisonment for minor 
                                                      
130 Jonathan P. Caulkins and Peter Reuter, “How drug enforcement affects drug prices,” Crime and Justice, vol. 
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drug-related cases may lead to overcrowding and to the infringement of the human rights of 
those imprisoned, and may exacerbate the transmission of HIV and other diseases among 
people who inject drugs. 
 
In many States, low-level offences such as small-scale drug dealing or trafficking are punished 
with harsher penalties than other serious crimes, raising questions about proportionate 
sentencing.136  
 
The United Nations Standard Minimum Rules for Non-custodial Measures (the Tokyo Rules)137 
encourage the use of non-custodial measures at all stages of criminal proceedings, including 
diversion and alternatives to pretrial detention, as well as alternatives to imprisonment at the 
sentencing and post-sentencing stages. They highlight that non-custodial measures serve to 
reduce overcrowding and to meet more effectively the social reintegration needs of offenders 
in the community. The Tokyo Rules recommend a wide range of non-custodial measures, 
suitable for different types of offences, which should be applied considering not only the 
nature and gravity of the offence but also the personality and background of the offender, the 
rights of victims and the protection of society.  
 
An example of a particular group that would benefit from this are the large number of women 
offenders worldwide who are imprisoned for minor drug-related offences, often as a result of 
manipulation, coercion and poverty. If involved in drug trafficking, women are usually minor 
players, their criminal offences often being an outgrowth of their own addiction or due to 
poverty and other pressures. A significant number of women are used as drug couriers to 
smuggle drugs across borders for small sums of money. They come from disadvantaged 
backgrounds and sometimes do not understand the risks involved and implications of the acts 
that they agree to perform. In the Bangkok Rules,138 Rule 61 provides specifically for mitigating 
factors to be taken into account when sentencing women, even where the offence may have 
been violent or may be considered a grave offence according to national law (e.g. drug 
trafficking).139 Bangkok Rule 64 establishes that non-custodial sentences for pregnant women 
and women with dependent children shall be preferred where possible and appropriate. 
 
In appropriate cases in which non-custodial measures and sanctions are used to replace 
imprisonment, they contribute directly to the reduction of the prison population. A further 
advantage of using alternatives to imprisonment is that they can help reduce reoffending, and 
thereby help reduce the prison population in the long term. Numerous studies have shown 
that reoffending rates are generally lower in the cases of those sentenced to non-custodial 
sanctions, in comparison to imprisonment. Further, recidivism itself can lead to a much higher 
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prospect of imprisonment for a second or third offence in some countries, resulting in a self-
perpetuating cycle of imprisonment and release.140  
 
Alternatives to imprisonment are often more effective at achieving important public safety 
objectives, such as greater security for the population, than imprisonment. Properly designed 
and implemented, they may infringe less on human rights while costing less in the short and 
long term.141 Consistent with international standards and norms (Tokyo Rules, Bangkok Rules), 
a number and variety of non-custodial measures and sanctions have been adopted. These 
include ensuring that police and prosecutors have sufficient discretion to divert suitable cases 
away from the criminal justice system, diversifying the number of alternatives available at the 
pretrial stage and restricting by law the use of pretrial detention. They may also include options 
for sentencing authorities to impose non-custodial sanctions instead of prison terms for non-
violent drug-related offences. Legislation that provides for alternatives to incarceration can 
better respond to the treatment and social reintegration needs of people who use drugs, such 
as those who have substance dependency and mental health care needs.142  
 
In order to be effective, the types of non-custodial measures used and their duration, 
conditions, supervision, treatment process and responses to breaches of conditions should 
respond to the individual situation, background, risks and needs of offenders.143 For example, 
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women have specific needs that are often better met in the community. Moreover, people 
with drug use disorders require treatment, which can in many cases be provided as an 
alternative to conviction or punishment. A review of existing practices in Member States shows 
that the range of options to provide treatment as an alternative is broad and includes measures 
at the pretrial stage (caution with a diversion to treatment, suspension of the prosecution, 
conditional dismissal, conditional bail), at the trial/sentencing stage (conditionally deferred 
sentence, conditionally suspended sentence, probation, special courts) and at the post-
sentencing stage (early conditional release or parole).144  
 
Drug courts, when underpinned by human rights and reasonable assumptions about their role, 
scale and limits, are viewed as a small but important piece of a broad diversion-based approach 
to drug-involved clients within court systems. While in some countries drug courts have been 
viewed as relatively successful, in others they are seen as well-meaning but ultimately failed 
experiments and a misdirection of drug treatment efforts towards the criminal justice rather 
than the public health system.145 
 
The application of the death penalty for drug-related offences does not respect the spirit of 
the international drug control conventions, and has the potential to become an obstacle to 
effective cross-border and international cooperation against drug trafficking, as the exchange 
of information and extradition on cases where the suspect may face capital punishment are 
prohibited in numerous national laws.146 In accordance with article 6(2) of the International 
Covenant on Civil and Political Rights, States that have not abolished the death penalty may 
impose it only for the “most serious crimes”, which has been consistently interpreted by UN 
human rights treaty bodies as those involving “intentional killing”.147 As such, drug offences 
must never serve as the basis for the imposition of the death penalty.148 The International 
Narcotics Control Board has encouraged all States that retain the death penalty for drug-
related offences to consider the abolition of the death penalty for drug-related offences.149 
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3.5 Legal guarantees and safeguards pertaining to criminal justice proceedings and the 
justice sector (including legal aid and the right to a fair trial) 
 
A central aspect of the 2030 Agenda is the concept of “leaving no one behind” and ensuring 
that those who are furthest behind are reached first. SDG Target 16.3 highlights the rule of law 
and equal access to justice, calling on countries to “promote the rule of law at the national and 
international levels and ensure equal access to justice for all”. Access to legal aid is 
fundamental in this regard, to ensure a criminal justice system is fair, humane, efficient and 
based on the rule of law, which can reduce the length of time suspects are held in custody and 
pretrial detention, congestion in the courts, wrongful convictions and prison overcrowding, 
while also being able to improve the conditions of prisoners serving their sentence and reduce 
rates of reoffending and victimization. Persons who are in contact with the criminal justice 
system because of drug offences, and persons living with HIV and other serious contagious 
diseases, are particularly vulnerable in this context. The UN Principles and Guidelines on Access 
to Legal Aid in Criminal Justice Systems150 specify in Principle 10 that special measures should 
be taken to ensure meaningful access to legal aid for drug users and persons living with HIV 
and other serious contagious diseases. However, Member States have not reported on the 
availability of these specialized services,151  while progress is visible regarding provision of 
services for children, persons with disabilities, and women.  
 
The large volume of drug-related offences for personal possession and drug use has led some 
States to seek methods to move cases more quickly through the criminal justice system. This 
has resulted in growth of the use of “trial waiver” systems. Although trial waiver systems do 
succeed in moving multiple cases through criminal justice systems, the price is often less 
procedural protection and judicial oversight.152 
 
3.6 Addressing links between drug trafficking and peace and security (money-
laundering, corruption, armed conflict, and political fragility and stability) 
 
The drug trade has been a significant source of income for some terrorist, insurgent and non-
State armed groups, while for others it has been one of many revenue streams or it may hardly 
have played a role at all. The most comprehensive evidence linking the terrorist groups on 
which the Security Council has imposed sanctions with the drug trade relates to the Taliban. 
The group has taxed entities involved in illicit drug production, manufacture and trafficking, 
and it has been directly involved in drug trafficking.153 UNODC estimated that terrorist and 
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insurgent groups raised about US$150 million in 2016 from the Afghan opiate trade in taxes 
levied on the cultivation of opium poppy and trafficking of opiates.154 
 
In contexts where drug trafficking syndicates or armed groups funded through drug money 
operate, these groups’ economic and coercive power has in several contexts quickly translated 
into political influence, undermining the integrity of state institutions and longer-term 
peacebuilding prospects, undermining the achievement of SDG 16, particularly Target 16.3 
“Promote the rule of law at the national and international levels and ensure equal access to 
justice for all”.155 
 
Drug trafficking also fuels corruption, going against SDG Target 16.5 “Substantially reduce 
corruption and bribery in all their forms”. Drug trafficking is extremely lucrative, making 
corruption of high-level and local level officials a prime vector for exercising political 
influence.156 
 
Opportunities for corruption exist at every stage of the drug production and supply chain. 
However, more research is needed on how different types of corruption interact with drug 
markets.157 
 
Organized crime and drug trafficking can also contribute directly and indirectly to violent 
conflict. The World Bank has identified trafficking in drugs as one of the major international 
stressors that need to be mitigated if a country is to move away from fragility and violence. 
The UN and World Bank have also argued that drug-related violence can reflect and exacerbate 
local grievances that ultimately lead to violent conflict.  
 
Different stages of the drug problem result in different manifestations of violence and can 
undermine the achievement of SDG Target 16.1 “Significantly reduce all forms of violence and 
related death rates everywhere”. Drug use may lead to violence related to the psychoactive 
effects of drugs (psychopharmacological violence), as well as to crime committed in order to 
obtain funds for purchasing drugs (economic violence). The intensity of drug-related violence 
is greatest, however, when associated with drug trafficking (systemic violence), as the example 
of Latin America shows. The traumatic effects of violence can also increase vulnerability to drug 
use.  
 
Yet drug trafficking and production do not necessarily produce violence, as illustrated by the 
low levels of homicide in transit countries affected by the opiate trafficking routes in Asia. 
Characteristics of the market and drug trafficking organizations may explain variations: market 
competition can generate violence in illicit markets, while differences in the internal structure 
of trafficking networks, which may be characterized by varying degrees of cohesiveness and 
hierarchy, can also play a role.  
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The profits associated with the drug trade are a key motivation for non-State armed groups, 
including terrorist organizations, to engage in or facilitate drug trafficking. In a number of 
countries, resources generated in illicit markets such as drug markets have played a role in 
complicating and extending armed conflicts, often increasing their overall lethality. In general, 
the drug trade flourishes where SDG 16, and particularly Targets 16.1–16.6, are far from being 
achieved: State presence is weak, where the rule of law is unevenly applied and where 
opportunities for corruption exist. At the same time, the wealth and power of drug trafficking 
organizations provide them with resources to buy protection from law enforcement agents, 
politicians and the business sector, thereby reinforcing corruption and further weakening the 
achievement of SDG 16.158 
 
Billions of dollars flow through the hands of drug trafficking organizations each year, having a 
large impact on local and wider economies and polities. Some recent global estimates suggest 
that the proceeds of drug sales accounted for slightly more than one quarter of overall 
revenues of transnational organized crime groups in 2014, with a maximum range from around 
one fifth to one third of such revenues. In recent years, drug-related income seems to have 
represented the second largest source of income — after counterfeiting of a broad range of 
goods — of transnational organized crime groups at the global level.159  
 
In the short term, an inflow of drug money can boost investment and local gross domestic 
product. But the long-term effects tend to be negative, particularly when drug-related 
proceeds comprise a sizeable portion of the total economy of a community or a country. 
Studies suggest that an injection of laundered money, including from illicit drug activities, is 
associated with reductions in overall annual economic growth rates, particularly in smaller and 
less developed countries. One estimate, based on a study of 17 countries of the Organization 
for Economic Cooperation and Development, suggests that a US$1 billion increase in money-
laundering could reduce overall economic growth by between 0.03 and 0.06 percentage 
points.160 
 
Profit is generated across the entire chain of drug production and distribution, but it is at the 
final stage that it tends to be highest. A UNODC study estimated that almost half of the profit 
made along the major heroin trafficking route from Afghanistan to Europe was generated in 
the four largest European consumer countries. Nevertheless, the size of the illicit economy 
associated with drugs, relative to the licit economy, tends to be higher in drug-producing 
countries, partly because of their relatively smaller economies.161 
 
The proceeds from drug trafficking can also complicate and undermine mediation and 
peacemaking efforts. A major source of funding for non-state armed groups in several 
contexts, proceeds from drug trafficking often translate into lowered incentives for these 
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groups to enter into ceasefire or peace agreements, or other forms of political settlements, 
thereby protracting conflicts. 
4.  Alternative development 
 
The reasons for cultivating illicit crops are diverse and often specific to particular areas. Illicit 
crop cultivation is linked, on the one hand, to the dynamics of cultivation itself and, on the 
other hand, to underlying drivers and root causes related to conditions of vulnerability found 
in geographical areas where cultivation takes place, such as weak rule of law or a lack of social 
and economic development. As survival and subsistence are real considerations for many 
households that engage in illicit crop cultivation, they are frequently risk averse and take a 
variety of elements into account when they make decisions on narcotic crop cultivation. While 
poverty can be a driver of illicit drug cultivation, not all poor farmers are involved in illicit crop 
cultivation and not all framers involved in illicit crop cultivation are poor.  
 
Alternative crop cultivation depends on many factors: possession of the requisite skills and 
knowledge for growing such crops; geographical and environmental factors, such as climate, 
the availability of water and arable land, and proximity to market; household-specific 
socioeconomic factors, such as level of income, existing employment opportunities, access to 
credit and size of landholding; developmental facilities such as access to roads, the power grid 
and educational and health services; and sociopolitical and institutional factors, such as 
interception risk, security, government control and rule of law.162 If development interventions 
are not sensitive to the vulnerabilities of communities to specific drug issues, they may 
inadvertently trigger dynamics that increase illicit cultivation.163 
 
Alternative development works when it has a long-term vision based on structural 
transformation, adequate funding and the political support to integrate it into a broader 
development and human rights agenda. Sustainable results in reducing illicit cultivation in 
different communities around the world can be obtained when the socioeconomic 
development of communities and the livelihood of rural households are improved. Viable, 
sustainable income-generating alternatives need to be available, and decent work 
opportunities strengthened, in order to decrease dependence on illicit cultivation over time. 
There is a general consensus that alternative development interventions can work only if they 
manage to achieve or build on the involvement of local communities or beneficiaries. Many 
successful alternative development programmes have a specific focus on women and their 
empowerment. Women can play a critical role in increasing the impact of alternative 
development.164 
 
Sequencing alternative development interventions is crucial to ensure that structural 
transformation and alternative livelihoods are functioning and providing adequate living and 
working conditions before eradication of illicit crops starts.165  
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Despite the amount of attention given to alternative development at the international level, 
and its crucial role in realizing SDG 8, there is a disconnect between international rhetoric and 
funding. Funding has decreased considerably in the last few years. Overall gross disbursements 
of alternative development funds from OECD countries declined by 71 per cent between 2009 
and 2013. In 2013, these disbursements accounted for just 0.1 per cent of global development 
assistance. 
5.  Cross-cutting (or topical) issues 
5.1 New psychoactive substances 
 
In recent years, hundreds of NPS have emerged; a total of 803 NPS were reported to UNODC 
during the period 2009–2017. However, while the global NPS market remains widely 
diversified, with the exception of a few substances, NPS do not seem to have established 
themselves on drug markets or replaced traditional drugs on a larger scale.166 The conditions 
are in place for an expansion of the NPS market (in terms of the numbers of substances), but 
there has been no sign of significant expansion to date. Most of the harm generated by drug 
use comes still from controlled substances (traditional classes) or non-medical use of 
prescription drugs rather than from NPS. 
 
Some studies have shown that selected groups of people are particularly vulnerable to NPS. 
Patterns of NPS use among marginalized, vulnerable and socially disadvantaged groups, 
including homeless people and people with mental health disorders, continue to be 
documented in some countries. High levels of use of NPS are reported by prisoners and people 
on probation, and this remains an issue of concern in numerous countries in Europe, North 
America and Oceania.167,  168 
 
The proliferation of NPS on the market has led the CND, following recommendations of the 
WHO, to prioritize international control of some of those substances. A 2014 UNODC-WHO 
Expert Consultation on NPS recognized the need to prioritize the international control of NPS 
that are more persistent, prevalent and harmful. The Expert Consultation concluded that a 
phased approach to NPS prioritization is required, with the two main criteria for consideration 
being evidence of harm (or potential harm) of a substance, and the prevalence (or proxies for 
prevalence) of its use. 169  Since 2015, the UN has taken action to place 39 NPS under 
international control. 
 
5.2 Non-medical use of pharmaceuticals  
 
The non-medical use of prescription drugs is becoming a major threat around the world.170 
Different pharmaceutical opioids are misused in different regions. In North America, illicitly 
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sourced fentanyl, mixed with heroin or other drugs, is driving the unprecedented number of 
overdose deaths.171 In Europe, the main opioid of concern remains heroin, but the non-medical 
use of methadone, buprenorphine and fentanyl has also been reported.172 In countries in West 
and North Africa, and the Near and Middle East, the non-medical use of tramadol, a 
pharmaceutical opioid that is not under international control, is emerging as a substance of 
concern. 173  The non-medical use of the common sedative/hypnotic benzodiazepines and 
similar substances is now one of the main drug use problems in some 60 countries. The misuse 
of benzodiazepines carries serious risks, not least an increased risk of overdose when used in 
combination with heroin. Benzodiazepines are frequently reported in fatal overdose cases 
involving opioids such as methadone.174 
 
5.3 Use of internet for drug-related activities 
 
Although the scale of drug trafficking on the darknet (that part of the “deep web” containing 
information that is only accessible using special web browsers) remains limited, it has shown 
signs of rapid growth.175 Authorities in Europe estimated that drug sales on the darknet from 
22 November 2011 to 16 February 2015 amounted to roughly US$44 million per year.176 
However, a later study estimated that, in early 2016, drug sales on the darknet were between 
$14 million and $25 million per month, equivalent to between $170 million and $300 million 
per year.177 
 
5.4 Social inclusion 
 
Marginalization can be viewed as contributing to illicit drug use, just as drug use can be viewed 
as contributing to the marginalization of some users: drug use can cause a deterioration in 
living conditions, while processes of social marginalization can be a reason for initiating drug 
use. Several risk factors for marginalization have been shown to be linked to drug use, including 
unemployment, homelessness, incarceration, sex work and vulnerable youth (such as young 
victims of family abuse and violence). In some societies, the stigma of being drug users and 
discrimination drive people who use drugs to the margins of society. People with drug use 
disorders are frequently distanced from their communities and families. The marginalization 
and stigmatization of people who regularly use drugs also have a negative impact on their 
employment opportunities and social relationships. 178, 179 
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5.5 Information (monitoring, epidemiology and statistics) 
 
Investment in data and evidence-based research pays off in more effective and efficient 
policies. In countries where adequate investments in data collection, research, monitoring and 
evaluation have been made and systems of government and civil society have been enhanced, 
more strategic, effective and efficient responses to illicit drug use and supply have been put in 
place. Up-to-date, comprehensive, disaggregated and transparent data are essential tools to 
understand drug use, its impact on health and development, drug supply, the dynamics of drug 
markets, and to evaluate drug control efforts. Data and analysis can measure the impact of 
illicit drug use, supply and drug control efforts on the enjoyment of human rights. Various tools 
are available to improve data and indicators. UNODC, WHO and UNAIDS have developed 
standards on drug epidemiology and drug supply and trafficking. OHCHR has also developed a 
set of human rights indicators for the realization of human rights,180 and guidance on a human 
rights-based approach to data collection in the implementation of the Sustainable 
Development Goals.181 All these tools – together with the multitude of statistical standards – 
can provide guidance in strengthening and streamlining existing data collection and analysis 
tools in drug control efforts. 
6.  Treaties and resolutions on international drug policy 
 
The three international drug control conventions regulate international policy on drugs. They 
are the 1961 Single Convention on Narcotic Drugs (with the 1972 Protocol to underscore, inter 
alia, the need to provide adequate prevention, treatment and rehabilitation services); the 
Convention on Psychotropic Substances of 1971; and the United Nations Convention against 
Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988. Member States reiterated 
at many occasions, most recently in the UNGASS 2016 outcome document that those three 
conventions, whose ultimate goal is to ensure the health, safety and well-being of all humanity, 
together with other international instruments, including in particular human rights treaties, 
constitute the cornerstone of the international drug control system. The General Assembly has 
consistently adopted resolutions declaring that international drug control must be carried out 
in conformity with the Charter, and “with full respect for human rights” (see resolutions 
A/RES/71/211, A/RES/72/198, A/RES/ 73/192; A/HRC/; see also UNGASS 2016).  
 
Beyond international treaties, international drug policy has evolved over the years through a 
series of resolutions, action plans and outcome documents agreed by different organs of the 
UN system. The CND, as the principal policymaking body of the UN with prime responsibility 
for drug-related matters, has over the past decade adopted over 120 resolutions covering a 
wide range of issues, including: prevention, treatment and care, HIV-AIDS prevention, and 
other health-related issues; promoting non-stigmatizing attitudes; the availability of and 
access to health services; enhancing the availability of controlled substances for medical and 
scientific purposes. Mainstreaming a gender perspective as well as implementing policies 
tailored to the specific needs of the most vulnerable members of society, including children 
and youth, were core elements in the resolutions adopted over the past decade. In 
                                                      
180 See www.ohchr.org/EN/Issues/Indicators/Pages/documents.aspx. 
181 See www.ohchr.org/EN/NewsEvents/Pages/DataForSustainableDevelopment.aspx. 
39 
 
addressing persistent and emerging challenges, the CND also approved resolutions on 
preventing and responding to the adverse health consequences and risks associated with the 
use of new psychoactive substances; on addressing the challenges posed by the non-medical 
use of synthetic opioids; and on the illicit trafficking of precursors and non-scheduled 
precursor chemicals. Other key topics such as promoting proportionate and effective policies, 
including alternatives to incarceration; preventing and countering of drug-related crime; 
addressing links with other forms of organized crime as well as socio-economic issues were as 
well addressed in Commission’s resolutions adopted during the last decade. On alternative 
development, the UN General Assembly and the CND have recognized that one of the drivers 
of illegal cultivation is poverty and lack of socioeconomic opportunities and repeatedly 
reaffirmed the commitment to address these root causes of illicit drug crop cultivation, 
including by tackling poverty and creating sustainable livelihood opportunities.182 
 
In addition to its resolutions, a number of which were recommended for adoption by the 
Economic and Social Council and the General Assembly, the Commission has in the past decade 
adopted three main policy documents: following review of the progress made in the 
implementation of the declarations and action plans adopted by the special session of the 
General Assembly in June 1998, the Commission on Narcotic Drugs adopted in March 2009 the 
Political Declaration and Plan of Action on International Cooperation towards an Integrated 
and Balanced Strategy to Counter the World Drug Problem, based on three pillars – demand 
reduction, supply reduction and international cooperation – and establishing 2019 as target 
date for the commitments made in operative paragraph 36. A high-level review was held in 
2014, resulting in the adoption of the 2014 Joint Ministerial Statement. Shortly thereafter, the 
General Assembly tasked the Commission to lead an open-ended and inclusive preparatory 
process for the Special Session on the World Drug Problem (UNGASS) held in April 2016, at 
which occasion the General Assembly adopted unanimously the outcome document “Our joint 
commitment to effectively addressing and countering the world drug problem”, which had 
been negotiated within the CND and which represents the most recent international consensus 
in drug policy.  
 
The UNGASS outcome document promotes a more comprehensive understanding of the world 
drug problem, with a number of issues that received less attention in previous documents. The 
outcome document demonstrates that health-related issues have come to play a more 
important role on the agenda of the CND, with topics of prevention of drug abuse, treatment 
and care as standing items on the work programme of the Commission, which is also reflected 
in the composition of the delegations at the Commissions’ meetings. The UNGASS outcome 
document recognizes that efforts to achieve the 2030 Agenda for Sustainable Development 
and to effectively address the world drug problem were complementary and mutually 
reinforcing. Member States for the first time included a whole chapter on the importance of 
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ensuring the availability of and access to controlled substances for medical and scientific 
purposes, including for the relief of suffering and pain. The document recognizes the 
importance of supply reduction and the need for criminal justice and law enforcement 
responses that adhere to principles of proportionality and the rule of law, and it further 
highlights persistent and emerging challenges, including new psychoactive substances, opioid 
overdoses and the use of the internet for drug-related activities. Member States also agreed 
on a set of recommendations on drugs and human rights, youth, children, women and 
communities, underscoring the importance of mainstreaming issues of gender and youth into 
drug-related policies and programmes. In addition, drug-related socioeconomic issues are 
covered within the document, which calls for long-term, comprehensive and sustainable 
development-oriented and balanced drug control policies and programmes. Other 
Commissions and UN bodies have agreed on recommendations and resolutions relevant to 
drugs.  
 
The General Assembly, the Human Rights Council, the Committee on Economic, Social and 
Cultural Rights, the Committee on the Rights of the Child, the Committee on the Elimination of 
Discrimination against Women, the Special Rapporteur on the right of everyone to the 
enjoyment of the highest attainable standard of physical and mental health and the Special 
Rapporteur on torture and other cruel, inhuman or degrading treatment or punishment have 
all considered that measures to minimize the adverse health consequences of drug use are 
essential for people who use drugs.183 
 
The United Nations Committee on the Elimination of Discrimination against Women, for 
example, has addressed drug issues and women on several occasions. The Committee 
recommended to provide health and counselling support to women with drug addiction in line 
with general recommendation No. 24 (1999) on women and health,184 and to ensure gender-
sensitive and evidence-based drug treatment services to reduce harmful effects for women 
who used drugs. The Committee has also expressed concerns about the excessive use of 
incarceration as a drug control measure against women and the ensuing female 
overpopulation in prison.185 
 
United Nations human rights mechanisms have reviewed a number of issues related to drugs. 
They have expressed concern about the unnecessary and disproportionate use of the criminal 
justice system for drug-related offences186  and the CND 187  has provided guidance on the 
promotion of proportionate sentencing for drug-related offences of an appropriate nature in 
implementing drug control policies. According to the OHCHR, proportionate sentencing is also 
relevant to pretrial detention for drug cases.188 The Convention against Torture and Other 
Cruel, Inhuman or Degrading Treatment or Punishment states that pretrial detention can be 
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used only as a last resort “for the shortest time possible, and only for the most serious 
offences”.189 
 
The International Covenant on Civil and Political Rights has stated the right to equality before 
courts and tribunals and to a fair trial as a key element of human rights protection. The right 
to be presumed innocent until proved guilty according to law is an essential element of the 
right to a fair trial.190  
 
The report of the High Commissioner for Human Rights to the Human Rights Council provided 
some practical examples of what may constitute a human rights violation in the criminal justice 
response to drug-related crime: the use of legal presumptions in some countries, whereby 
persons found with amounts of drugs above specified thresholds, or in possession of keys to a 
building or vehicle where drugs have been found, are presumed to be guilty of drug trafficking, 
has been condemned as reversing the burden of proof in criminal proceedings, and may 
amount to a violation of the right to a fair trial.191  
 
In accordance with the Human Rights Committee, physical and mental pain and suffering 
associated with withdrawal symptoms may amount to torture or ill-treatment. 192  The 
Committee against torture discouraged the use of solitary confinement as a “management 
method” in compulsory isolation drug treatment centres.193  
 
Several international human rights mechanisms, as well as 11 UN entities, considered that a 
major obstacle to accessibility of treatment is the criminalization of personal use and 
possession of drugs for other than medical and scientific purposes, and recommended that 
consideration be given to removing obstacles to the right to health, including by refraining 
from imposing criminal penalties for the personal use and possession of drugs, within the 
flexibility allowed by the international drug control conventions.194 
 
The Committee on Economic, Social and Cultural Rights,195 the Special Rapporteurs on the right 
to health; on freedom from torture and other ill-treatment; and on extrajudicial, summary or 
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arbitrary executions; 196 the Committee on the Rights of the Child;197 and the Office of the 
United Nations High Commissioner for Human Rights 198  have recommended the 
decriminalization of drug use and possession for personal use as an important step towards 
fulfilling the rights to health and towards protecting the safety and well-being of communities. 
Twelve UN agencies have jointly recommended reviewing and repealing laws criminalizing drug 
use and the possession of drugs for personal use. 199  The World Health Organization has 
recommended that countries work towards the decriminalization of drug use as a strategy to 
reduce incarceration and support access to HIV-related services for people who use drugs.200 
 
With regard to the eradication of illicit crops, international human rights mechanisms have 
emphasized that it should not negatively affect the environment or the health and welfare of 
farmers, their families or other stakeholders. International human rights mechanisms objected 
to aerial spraying for crop eradication because of the harm it can cause to farmers and their 
children, as well as to environment.201 
7. Concluding observations  
 
From the UN’s experience over the last decade, it is clear that the multifaceted nature of the 
problem requires a comprehensive, multidisciplinary approach that includes targeted law 
enforcement efforts to dismantle organized crime and ensure the physical security of people, 
alongside efforts that promote health, good governance and sustainable development 
underpinned by the drug control conventions, human rights laws, principles and standards, 
such as the principles of equality and non-discrimination. Let us not forget that the health and 
welfare of humankind are the fundamental underpinnings of the three international drug 
control conventions, which form the cornerstone of the international drug control system. The 
drug control conventions therefore allow countries sufficient flexibility to design and 
implement national drug policies according to their priorities and needs, consistent with the 
principle of common and shared responsibility. As emphasized by UNGASS, the 2030 Agenda 
for Sustainable Development and the international drug control conventions, international 
human rights treaties and other relevant instruments are complementary and mutually 
reinforcing.  
 
The UN system remains committed to supporting Member States in developing and 
implementing truly balanced, comprehensive, integrated, evidence-based, human rights-
                                                      
196Office of the High Commissioner for Human Rights (15 April 2016), Joint Open Letter by the UN Working Group 
on Arbitrary Detention; the Special Rapporteurs on extrajudicial, summary or arbitrary executions; torture and 
other cruel, inhuman or degrading treatment or punishment; the right of everyone to the highest attainable 
standard of mental and physical health; and the Committee on the Rights of the Child, on the occasion of the 
United Nation General Assembly Special Session on Drugs. Available at https://www.ohchr.org/ 
Documents/Issues/Health/UNGASS-joint_OL_HR_mechanisms_April2016.pdf 
197 Ibid. 
198 Report of the United Nations High Commissioner for Human Rights: Study on the impact of the world drug 
problem on the enjoyment of human rights, 4 September 2015, A/HRC/30/65. 
199UNAIDS/UNHCR/UNICEF/WFP/UNDP/UNFPA/UN Women/ILO/UNESCO/WHO/IOM/OHCHR, Joint United 
Nations Statement on ending discrimination in health care, 27 June 2017. 
200 WHO, Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations (2014); 
see also UNODC, Handbook on strategies to reduce overcrowding in prisons (2013), pp. 29–30 and 55–57. 
201 See CRC/C/COL/CO/3, A/HRC/4/32/Add.2, A/HRC/7/11/Add.3 and A/HRC/4/30/Add.1. 
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based, development-oriented and sustainable responses to the world drug problem, within 
the framework of the 2030 Agenda for Sustainable Development, and as envisaged by the 
operational chapters of the UNGASS outcome document. By working together through the 
Task Team (the “UN system coordination Task Team on the Implementation of the UN System 
Common Position on drug-related matters”), the UN system can provide the kind of 
multidisciplinary support to Member States that can deliver more effective, evidence-based 
and humane drug control policies that help rather than hinder a country’s efforts to achieve 
its Sustainable Development Goals and to “leave no one behind”. For more information on 
these latest efforts by the UN system to better support Member States, please see the UN 
System Common Position adopted in November 2018 to support the implementation of the 
international drug control policy through effective inter-agency collaboration (Annex I); the 
summary of key messages resulting from the knowledge produced and acquired by the UN 
system on drug-related matters (Annex II); and the examples of existing joint programmes 
between UN entities on drug-related matters (Annex III). Going forward, on the basis of the 
evidence produced in this brief, the members of the Task Team202  will continue to work 
together to produce evidence-based briefs on the links between drug policies and sustainable 
development, and to deliver integrated assistance through joint programmes. This can support 
Member States in designing and implementing effective drug policies that meet international 
standards and obligations. As highlighted by the Secretary General, the Task Team encourages 
interested donors to provide support to its work, so that it can continue to produce tailor-
made evidence in support of the needs of Member States, as well as continue to deliver 
integrated assistance through its existing joint programmes and through new kinds of 
partnerships.  
 
 
  
                                                      
202 Current membership of the Task Team: UNODC, UNDP, OHCHR, UNAIDS, WHO, DPPA, UNESCO, UN Women, 
UNICEF, UN-Habitat, ECLAC, ILO, ICAO, IMO, UPU and UNU.  
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Annex I 
 
United Nations system common position supporting the 
implementation of the international drug control policy through 
effective inter-agency collaboration203 
 
Shared principles 
 
Reiterating our strong commitment to supporting Member States in developing and 
implementing truly balanced, comprehensive, integrated, evidence-based, human rights-
based, development-oriented, and sustainable responses to the world drug problem, within 
the framework of the 2030 Agenda for Sustainable Development, we, the members of the 
United Nations system, underline the importance of the following common values:  
 
• We commit to supporting the practical implementation of the outcome of the 2016 
United Nations General Assembly Special Session (UNGASS) in April 2016 as a 
blueprint for action, charting a path that promotes more effective and humane drug 
control policies, supporting the Sustainable Development Goals’ commitments to 
leave no one behind;  
 
• We recognize that the world drug problem is complex and multifaceted and that 
challenges posed by drugs have wide-ranging adverse impacts on security, human 
rights and development;  
 
• We underscore that the multifaceted nature of the problem requires a 
comprehensive approach that includes law enforcement efforts ensuring people’s 
security as well as efforts promoting health, human rights, including equality and 
non-discrimination, and sustainable development; 
  
• We commit to promoting a truly evidence-based, balanced approach, whereby 
sufficient attention is given to measures that address the root causes of drug abuse, 
cultivation and other involvement in the drug trade; 
  
• We acknowledge that we have a common and shared responsibility to work 
together, particularly through the Commission on Narcotic Drugs (CND), to pursue a 
coordinated, balanced and comprehensive approach, leading to evidence-based and 
sustainable solutions;  
 
• We recognize that the concern with the health and welfare of humankind underpins 
the three international drug control conventions, which, together with other 
relevant international instruments, are the cornerstone of the international drug 
control system;  
                                                      
203 Decision of the United Nations Chief Executives Board for Coordination (CEB/2018/2), Second regular 
session of 2018, Manhasset, New York, 7 and 8 November 2018, available at: 
https://www.unsceb.org/CEBPublicFiles/CEB-2018-2-SoD.pdf  
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• We acknowledge that the conventions allow for sufficient flexibility for countries to 
design and implement national drug policies according to their priorities and needs, 
consistent with the principle of common and shared responsibility and applicable 
international law; 
  
• We acknowledge that the international drug control conventions, international 
human rights treaties and other relevant instruments, and the 2030 Agenda for 
Sustainable Development are complementary and mutually reinforcing. National 
drug control programmes, strategies and policies should be designed and 
implemented by States in accordance with their human rights obligations.  
 
Scope and purpose  
 
• To guide approaches across the UN system, stepping up efforts to ensure that no 
one is left behind; 
  
• To inspire planning and implementation of UN activities, including joint inter-agency 
activities; 
  
• To speak with one voice and raise awareness of the multifaceted nature of the world 
drug problem.  
 
Directions for action  
 
In addition to our ongoing efforts, we commit to harnessing synergies and strengthening 
inter-agency cooperation, making best use of the expertise within the UN system, to further 
enhance consistent sharing of information and lessons learned as well as the production of 
more comprehensive data on the impact of drug policies, including with a view to supporting 
the implementation of the 2030 Agenda for Sustainable Development.  
 
We, therefore, commit to stepping up our joint efforts and supporting each other to, inter 
alia:  
 
• To support the development and implementation of policies that put people, 
health and human rights at the centre, by providing a scientific evidence-based, 
available, accessible and affordable recovery-oriented continuum of care based 
upon prevention, treatment and support; and promote a rebalancing of drug 
policies and interventions towards public health approaches; 
  
• To promote the increased investment in measures aimed at minimizing the 
adverse public health consequences of drug abuse, by some referred to as harm 
reduction, which reduce new HIV infections, improve health outcomes and 
deliver broader social benefits by reducing pressure on health-care and criminal 
justice systems; 
  
• To ensure the provision of drug prevention, treatment, rehabilitation and general 
support services, including health care and social protection also in prison 
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settings, ensuring that they are equivalent to and that they provide continuity of 
care with those in the community;  
 
• To ensure the respect for the dignity and human rights for people who use drugs 
in all aspects of drug and social policies, including equal access by people who 
use drugs to public services including housing, health care and education;  
 
• To call for Universal Health Coverage (UHC) for people with drug use disorders 
and positioning of drug use disorders as other health conditions that should be 
included in the overall UHC framework in national health systems; 
  
• To enhance access to controlled medicines for legitimate medical and scientific 
purposes including the relief of pain and treatment of drug dependence; 
  
• To enhance international support for effective capacity-building in developing 
countries to support the implementation of all the Sustainable Development 
Goals, including through North-South, South-South and triangular cooperation;  
 
• To support the identification of prevalent, persistent and harmful psychoactive 
drugs including new psychoactive substances and their associated health risks, 
using global and regional agencies’ early warning and alert systems; 
  
• To provide guidance and technical assistance to strengthen cross-border law 
enforcement and judicial cooperation;  
 
• To promote sustainable livelihoods through adequately-sequenced, well-funded 
and long-term development-oriented drug policies in rural and urban areas 
affected by illicit drug activities, including cultivation, production and trafficking, 
bearing in mind environmental protection and sustainability; 
  
• To promote alternatives to conviction and punishment in appropriate cases, 
including the decriminalization of drug possession for personal use, and promote 
the principle of proportionality; address prison overcrowding and over-
incarceration by people accused of drug crimes; support implementation of 
effective criminal justice responses that ensure legal guarantees and due process 
safeguards pertaining to criminal justice proceedings and ensure timely access to 
legal aid and the right to a fair trial; and support practical measures to prohibit 
arbitrary arrest and detention and torture; 
  
• To call for changes in laws, policies and practices that threaten the health and 
human rights of people; 
  
• To promote measures aimed at reducing stigma and elimination of discrimination 
and achieving universal coverage of evidence-based prevention, treatment, and 
rehabilitation; 
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• To cooperate to ensure human rights-based drug control and address impunity 
for serious human rights violations in the context of drug control efforts; 
  
• To assist Member States in implementing non-discriminatory policies, including 
with regard to ethnicity, race, sex, language, religion, or other status; 
  
• To promote the active involvement and participation of civil society and local 
communities, including people who use drugs, as well as women and youth; 
  
• To provide Member States with a necessary evidence base to make informed 
policy decisions and to better understand the risks and benefits of new 
approaches to drug control, including those relating to cannabis; 
  
• To compile, analyse and produce data reflecting UN system-wide practices and 
lessons-learned in drug-related matters, and produce system-wide data and 
analysis, including in light of the 2019 Ministerial segment of the CND and the 
advancement of the implementation of the 2030 Agenda for Sustainable 
Development.  
 
Accountability and operationalization  
 
We commit to supporting each other’s activities, within our mandates, and to delivering 
balanced, comprehensive, integrated, evidence-based, human rights-based, development-
oriented, and sustainable support to Member States in implementing joint commitments, 
including the operational recommendations contained in the outcome document of the 
2016 United Nations Special Session on the World Drug Problem.  
 
With a view to ensuring coherent efforts to realise the commitments under this US System 
Common Position and, in particular, coordinated data collection to promote scientific, 
evidence-based implementation of international commitments,204 we establish a UN-system 
Coordination Task Team, led by UNODC, of interested UN system entities, including those 
with expertise in the collection of drug-related data, within the framework of the Secretary-
General’s Executive Committee.  
 
  
                                                      
204 Working in line with the principles governing international statistical activities (E/CN.3/2006/13, 
annex), as endorsed by the Committee for the Coordination of Statistical Activities. 
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Annex II 
 
Summary of key messages based on the knowledge produced and 
acquired by the UN system on drug-related matters 
 
Entities of the UN system have a common and shared responsibility to work together to pursue 
a coordinated, balanced and comprehensive approach, leading to evidence-based and 
sustainable solutions. As shown in this brief, there is a body of solid evidence that can guide 
the action of the UN system and Member States to ensure that policies and programmes are 
effective and in line with international standards. Based on this evidence and on the UN System 
Common Position, the following key messages guide UN action to support Member States with 
cost-effective and humane solutions.  
 
Overall approach 
 
• When it comes to addressing stigma and discrimination, not only do health service 
providers need to be educated, but people who use drugs should be protected from 
human rights abuses and discrimination by law. 
 
• People and their health and human rights need to be put at the centre, by providing a 
scientific evidence-based, available, accessible and affordable recovery-oriented 
continuum of care based upon prevention, treatment and support.  
 
• There is the need to assist Member States in implementing non-discriminatory policies, 
including with regard to ethnicity, race, sex, language, religion or other status.  
 
• It is key to promote the active involvement and participation of civil society and local 
communities, including people who use drugs, as well as women and youth.  
 
• Investing in data collection, analysis and research, at national, regional and global levels, 
based on international standards and best practices is required to generate the 
evidence needed to make informed policy decisions and to better understand the risks 
and benefits of new approaches to drug control, including those relating to cannabis.  
 
Health, including the availability of and access to controlled medicines 
 
• A respect for the dignity and human rights for people who use drugs must be ensured 
in all aspects of drug and social policies, including equal access by people who use drugs 
to public services such as housing, health care and education. 
 
• There is the need to achieve Universal Health Coverage (UHC) for people who use drugs 
and to position drug dependence and other drug-related issues as health conditions 
that should be included in the overall UHC framework in national health systems.  
 
• Treatment services for drug use disorders should comply with human rights obligations 
and recognize the inherent dignity of all individuals. This includes responding to the 
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right to receive the highest attainable standard of health and well-being and ensuring 
non-discrimination. All interventions offered should meet the highest ethical 
requirements, following the application of the Universal Declaration of Human Rights 
on treating all patients and clients with respect and empathy.  
 
• Measures aimed at reducing stigma, the elimination of discrimination and achieving 
universal coverage of evidence-based prevention, treatment and rehabilitation should 
be promoted. 
 
• The provision of drug prevention, treatment, rehabilitation and general support 
services is a necessity, including health care and social protection also in prison settings, 
ensuring that they are equivalent to and that they provide continuity of care with those 
in the community; there is the need to invest also in data collection and information 
systems to monitor the drug situation in prison settings.  
  
• Increased investment in measures aimed at minimizing the adverse public health 
consequences of drug use, which reduce new HIV and viral hepatitis infections, provide 
treatment and care for drug users with HIV, TB and viral hepatitis, improve other health 
outcomes and social reintegration of people who use drugs, and deliver broader social 
benefits, including by reducing pressure on health care and criminal justice systems. 
These interventions work and are cost-effective, while also helping introduce people 
who use drugs to health and social services.  
 
• Controlled drugs should be accessible for legitimate medical and scientific purposes, 
including the relief of pain and treatment of drug dependence. 
 
Prevention of and responses to drug-related crime 
 
• Guidance and technical assistance provided to Member States strengthens cross-
border law enforcement and judicial cooperation. Support regional and international 
cooperation following the model of regional centres.  
 
• Changes are required in laws, policies and practices that threaten the health and 
human rights of people. 
 
• Ensuring human rights-based drug control and addressing impunity for serious human 
rights violations in the context of drug control efforts requires cooperation.   
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Countering illicit traffic in narcotic drugs and psychotropic substances  
 
• There is a need to change the target for success among law enforcement agencies: 
from quantities seized to the dismantling of drug trafficking organizations. This requires 
a higher level of sophistication and the development of a critical mass of basic 
knowledge among law enforcement and specialized units. Organized criminal groups 
are changing their business model, so law enforcement requires training to understand 
these new dynamics and to design effective actions. Best results come when there is 
effective coordination among national institutions.  
 
• Community policing and precision policing using detailed data and information at local 
level need to be enhanced. Law enforcement organizations should be trained where 
needed to fully respect human rights and understand gender perspectives. 
Cooperation and joint training between law enforcement and public health 
professionals produces the best outcomes. When law enforcement cooperates with 
public health, lives are saved, crime is reduced and health is improved.  
 
Proportionate and effective policies and responses (including evidence on alternatives to 
incarceration and decriminalization/depenalization of drug use) 
 
• Alternatives to conviction and punishment in appropriate cases are to be promoted, as 
is the non-criminalization of drug use and drug possession for personal use, while 
espousing public health and administrative measures that seek to prevent illicit drug 
use, including the promotion of the principle of proportionality; address prison 
overcrowding and over-incarceration by people accused of drug crimes; support 
implementation of effective criminal justice responses that ensure legal guarantees 
and due process safeguards pertaining to criminal justice proceedings and ensure 
timely access to legal aid and the right to a fair trial; and support practical measures to 
prohibit arbitrary arrest and detention and torture. Proportionality can be 
implemented in the different steps of designing criminal justice responses: in law, in 
applying the law, and in sentencing. The Secretary General calls on Member States that 
continue to impose and implement death sentences, to declare and implement a 
moratorium on executions with a view to abolishing the death penalty.205 States that 
have not yet abolished the death penalty may only impose it for the “most serious 
crimes,” under strict adherence to fair trial safeguards and due process, and it should 
never be mandatory.206 
 
• The Tokyo Rules, the Bangkok Rules, the Mandela Rules, and the UN Principles and 
Guidelines on Access to Legal Aid in Criminal Justice Systems, are practical instruments 
to develop human rights-based criminal justice responses to drug crime and need to be 
fully implemented; taking a people-orientated approach in designing a criminal justice 
response that focuses on the offender rather than the offence is important.  
 
                                                      
205 A/HRC/39/19, para. 48. 
206 Ibid., para. 54, and Capital punishment and implementation of the safeguards guaranteeing protection of the 
rights of those facing the death penalty, E/2015/49, para. 130. 
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Legal guarantees and safeguards pertaining to criminal justice proceedings and the justice sector 
(including legal aid and the right to a fair trial) 
 
• There is a lack of information on access to legal aid and a fair trial for drug offences. 
Promoting a fair trial and avoiding discrimination remains essential for criminal justice 
responses, but more investment is needed to collect data and to regularly monitor the 
implementation of these principles.   
 
Alternative development 
 
• Sustainable livelihoods need to be promoted through adequately-sequenced, well-
funded and long-term development-oriented drug policies in rural and urban areas 
affected by illicit drug activities, including cultivation, production and trafficking, 
bearing in mind environmental protection and sustainability, and the need to monitor 
and evaluate alternative programmes to ensure that they provide an effective solution.  
 
• It is essential that employment creation strategies focus not only on the provision of 
decent work but also target the structural transformation needed to tackle the supply 
side of the world drug problem. As highlighted in the United Nations Guiding Principles 
on Alternative Development, employment programs at both local and national levels 
should be designed through community dialogue and participation and aim to achieve 
inclusive economic growth that contributes to poverty eradication.   
 
New psychoactive substances (NPS) 
 
• The identification of prevalent, persistent and harmful psychoactive drugs, including 
new psychoactive substances and their associated health risks, is best achieved using 
early warning and alert systems; an important component is understanding and taking 
into consideration the impact of regulating NPS on marginalized groups of people who 
use drugs.  
 
• Services are required to minimize the adverse public health consequences of drug use, 
and drug treatment services targeted at people who use NPS are needed. 
 
Non-medical use of pharmaceuticals 
 
• A broad range of interventions are needed to address the non-medical use of 
pharmaceuticals: control and awareness and the monitoring of prescription practices, 
as well as the promotion of the UN guidelines on prescriptions.  
 
• It is necessary to maximize both the protection of health and access to prescription 
medicines, while avoiding misuse and dependency. 
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Annex III  
 
Examples of joint programmes between UN entities on drug-related 
matters 
 
 
UNODC – WHO Treatment 
 
UNODC – WHO NPS 
UNODC – UNAIDS – WHO – World Bank Joint estimates on PWID, HIV, HCV 
 
ICU – UNODC – WHO – INCB  Access to controlled medicines 
Civil society – UNAIDS – WHO – UN Women 
– UNDP 
Global partnership to end all forms of 
discrimination 
Inter-Agency Technical Working Group on 
Drug Epidemiology (WHO, UNODC, UNAIDS, 
AU, EMCDDA, OAS, Pompidou Group) 
 
Drug statistics 
UNODC – WCO Container Control Program 
UNODC – INTERPOL – Transparency 
International 
CRIMJUST: strengthening criminal 
investigation and criminal justice 
cooperation along the cocaine routes in 
Latin America, the Caribbean and West 
Africa 
UNODC – Interpol – WCO Airport Communication Project (AIRCOP) 
UNESCO – UNODC – WHO Effective education sector responses 
UNODC – UNOWAS – Department of 
Political and Peacebuilding Affairs (DPPA) – 
Department of Peace Operations (DPO) –
INTERPOL 
West African Coast Initiative (WACI) 
 
 
 
